

Academic Calender MBBS Batch 2023-2024 (MBBS 2nd PROF)

	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug
Mon												
Tue		1						1			1 Preparatory Leave	
Wed		2 Gandhi Jayanti			1 New year			2			2 Preparatory Leave	
Thu		3			2			3 Term II	1		3 Preparatory Leave	
Fri		4	1 GH		3			4 Term II	2		4 Preparatory Leave	1
Sat		5	2 Govardhan Puja		4	1	1	5 Term II	3		5 Preparatory Leave	2
Sun	1	6	3 Bhaidooj	1	5	2	2	6 Ram Navmi	4	1	6	3
Mon	2	7	4	2	6 Term I	3	3	7 Term II	5	2	7 Pre-University Exams	4
Tue	3	8	5	3	7 Term I	4	4	8 Term II	6	3 FMT Term Exam	8 Pre-University Exams	5
Wed	4	9	6	4	8 Term I	5	5	9 Term II	7	4	9 Pre-University Exams	6
Thu	5	10	7	5	9 Term I	6	6	10 Term II	8	5	10 Pre-University Exams	7
Fri	6	11	8	6	10 Term I	7	7 Med Term Exam	11 Term II	9	6 Id-UI-Adha	11 Pre-University Exams	8
Sat	7	12	9	7	11 Term I	8	8	12	10	7	12 Pre-University Exams	9 Raksha Bandhan
Sun	8	13	10	8	12	9	9	13	11	8	13	10
Mon	9	14	11	9	13 Term I	10	10	14	12	9 Summer Vacations	14 Pre-University Exams	11
Tue	10	15	12	10	14 Term I	11	11	15	13	10 Summer Vacations	15 Pre-University Exams	12
Wed	11	16	13	11	15	12	12	16	14	11 Summer Vacations	16 Pre-University Exams	13
Thu	12	17	14	12	16	13	13	17	15	12 Summer Vacations	17 Pre-University Exams	14
Fri	13	18	15 Guru Nanak Jayanti	13	17	14	14 Holi	18 Good Friday	16	13 Summer Vacations	18 Pre-University Exams	15 Independence
Sat	14	19	16	14	18	15	15	19	17	14 Summer Vacations	19 Pre-University Exams	16 Janmashtami
Sun	15	20	17	15	19	16	16	20	18	15	20	17
Mon	16 Batch starts	21	18	16	20	17	17	21	19	16	21	18 University Exams
Tue	17	22	19	17	21	18	18	22	20	17	22	19
Wed	18	23	20	18	22	19	19	23	21	18	23	20

Thu	19	24	21	19	23	20	20	24	22	19	24	21
Fri	20	25	22	20	24	21 Surgery term Exam	21	25	23	20	25	22
Sat	21	26	23	21	25 CM Term Exam	22	22	26	24	21	26	23
Sun	22	27	24	22	26 Republic Day	23	23	27	25	22	27	24
Mon	23	28	25	23	27	24	24	28	26	23	28	25
Tue	24	29	26	24	28	25	25	29	27	24	29	26
Wed	25	30	27	25 Christmas	29	26	26	30	28	25	30	27
Thu	26	31 Deepawali	28	26 Winter Vacations	30	27 O&G Term Exam	27		29	26	31	28
Fri	27		29	27 Winter Vacations	31	28	28		30	27		29
Sat	28		30	28 Winter Vacations			29		31	28		30
Sun	29			29 Winter Vacations			30			29		31
Mon	30			30 Winter Vacations			31			30 Preparatory Leave		
Tue				31 Winter Vacations								
Total	13	25	23	20	18	24	25	17	27	17	11	11
												231 days/ 38 weeks

P.N. Dates of Term, Pre- University exams, Summer & Winter vacations are tentative, subject to change



S.N.	Date	OG	DR	GM	PE	DE	CM	GS	OR
		(7wks)	(2 wks)	(9 wks)	(4wks)	(1 wks)	(4wks)	(7 wks)	(2 wks)
1	16-29 Sep '24	A+B+C		D+E+F	G+H+I			J+K+L	
2	30 Sep- 13 Oct'24	A+B+C		D+E+F	G+H+I			J+K+L	
3	14-20 Oct'24	A+B+C		D+E+F		G+H+I		J+K+L	
4	21-27 Oct'24	A+B+C		D+E+F			G+H+I	J+K+L	
5	28 Oct- 10 Nov'24	A+B+C		D+E+F			G+H+I	J+K+L	
6	11-24 Nov'24		A+B+C	D+E+F			G+H+I		J+K+L
7	25 Nov-8 Dec'24	J+K+L		A+B+C	D+E+F			G+H+I	
8	9-22 Dec'24	J+K+L		A+B+C	D+E+F			G+H+I	
9	23 Dec-19 Jan'24	J+K+L		A+B+C		D+E+F		G+H+I	
10	20-26 Jan'24	J+K+L		A+B+C			D+E+F	G+H+I	
11	27 Jan-2 Feb'24	J+K+L		A+B+C			D+E+F	G+H+I	
12	3-16 Feb'24		J+K+L	A+B+C			D+E+F		G+H+I
13	17 Feb-2 Mar'24	G+H+I		J+K+L	A+B+C			D+E+F	
14	3-16 Mar'24	G+H+I		J+K+L	A+B+C			D+E+F	
15	17-23 Mar'24	G+H+I		J+K+L		A+B+C		D+E+F	
16	24-30 Mar'24	G+H+I		J+K+L			A+B+C	D+E+F	
17	31 Mar -13 Apr '24	G+H+I		J+K+L			A+B+C	D+E+F	
18	14-27 Apr '24		G+H+I	J+K+L			A+B+C		D+E+F
19	28 Apr- 11 May '24	D+E+F		G+H+I	G+H+I			A+B+C	
20	12-25 May '24	D+E+F		G+H+I	G+H+I			A+B+C	
21	26 May- 1 Jun '24	D+E+F		G+H+I		G+H+I		A+B+C	
22	2-15 Jun '24	D+E+F		G+H+I			G+H+I	A+B+C	
23	16-29 Jun '24	D+E+F		G+H+I			G+H+I	A+B+C	
24	30 Jun- 2 Aug'24		D+E+F	G+H+I			G+H+I		A+B+C
25	3-17 Aug'24*		D+E+F	G+H+I			G+H+I		A+B+C

*Can be used as reserve posting

**GM- General Medicine, SU-Surgery, OG –Obstetrics & Gynaecology, CM-Community Medicine,
PE- Paediatrics, DR-Dermatology, OR-Orthopedics, DE -Dentistry**

Batch will be divided in the following groups :					
Batch	Roll No	Batch	Roll No	Batch	Roll No
A	2305131300001 to 00025	E	2305131300095 to 00119	I	2305131300190 to 00212
B	2305131300026 to 00048	F	2305131300120 to 00142	J	2305131300214 to 00233
C	2305131300049 to 00071	G	2305131300143 to 00165	K	2305131300234 to 00250
D	2305131300072 to 00094	H	2305131300166 to 00189	L	Supple Students (Batch 2021,2022)

RAMA MEDICAL COLLEGE HOSPITAL & RESEARCH CENTRE, HAPUR

TIME TABLE MBBS PHASE II (BATCH 2023-2024)

From 16 Sep'24 - 25 Jan'25

DAY	8-9 am	9- 10am	10-11 am	11 am -12 noon	12-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Mon	Path (L-)	Clinical Posting			Micro (L-)	Lunch	Pharm (SGT-)		
Tue	Pharm (L-)	Clinical Posting			Com. Med (SDL)	Lunch	Micro (SGT-)		
Wed	Micro (L-)	Clinical Posting			Pharm (L-)	Lunch	Path (SGT-)		
Thu	Path (L-)	Clinical Posting			O & G (L-)	Lunch	Path (SGT-)		
Fri	Surg (L)	Clinical Posting			Med (L-)	Lunch	Pharm (SGT-)		
Sat	Com. Med (L)	AETCOM Module	AETCOM Module	Pharm (L-)	Path (L-)	Lunch	Micro (SGT-)		Sports/ECA
3r d Saturday- Community Medicine- Family Adoption Program									

N.B.: 3r d Saturday 10-1 pm will be Family Adoption Program, Community Medicine

From 26 Jan - 27 Feb'25

DAY	8-9 am	9- 10am	10-11 am	11 am -12 noon	12-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
Mon	Path (L-)	Clinical Posting			Micro (L-)	Lunch	Pharm (SGT-)		
Tue	Pharm (L-)	Clinical Posting			F.M.T (SGT)	Lunch	Micro (SGT-)		
Wed	Micro (L-)	Clinical Posting			Pharm (L-)	Lunch	Path (SGT-)		
Thu	Path (L-)	Clinical Posting			O & G (L-)	Lunch	Path (SGT-)		
Fri	Surg (L)	Clinical Posting			Med (L-)	Lunch	Pharm (SGT-)		
Sat	F.M.T (L/SDL-)	AETCOM Module	AETCOM Module	Pharm (L-)	Path (L-)	Lunch	Micro (SGT-)		Sports/ECA
			3r d Saturday- Community Medicine- Family Adoption Program						

N.B.: 3r d Saturday 10-1 pm will be Family Adoption Program, Community Medicine

From 28 Feb - 15 Mar'25

DAY	8-9 am	9- 10am	10-11 am	11 am -12 noon	12-1 pm	1-2 pm	2-3 pm	3-4 pm	
-----	--------	---------	----------	----------------	---------	--------	--------	--------	--

Mon	Path (L-)	Clinical Posting			Micro (L-)	Lunch	Pharm (SGT-)	
Tue	Pharm (L-)	Clinical Posting			F.M.T (SGT)	Lunch	Micro (SGT-)	
Wed	Micro (L-)	Clinical Posting			Pharm (L-)	Lunch	Path (SGT-)	
Thu	Path (L-)	Clinical Posting			Pharm (SDL-)	Lunch	Path (SGT-)	
Fri	Surg (L)	Clinical Posting			Med (L-)	Lunch	Pharm (SGT-)	
Sat	F.M.T (L/SDL-)	AETCOM Module	AETCOM Module	Pharm (L-)	Path (L-)	Lunch	Micro (SGT-)	
			3r d Saturday- Community Medicine- Family Adoption Program					

N.B.: 3rd Saturday 10-1 pm will be Family Adoption Program, Community Medicine

From 16 Mar'25 onwards

DAY	8-9 am	9- 10am	10-11 am	11 am -12 noon	12-1 pm	1-2 pm	2-3 pm	3-4 pm	
Mon	Path (L-)	Clinical Posting			Micro (L-)	Lunch	Pharm (SGT-)		
Tue	Pharm (L-)	Clinical Posting			F.M.T (SGT)	Lunch	Micro (SGT-)		
Wed	Micro (L-)	Clinical Posting			Pharm (L-)	Lunch	Path (SGT-)		
Thu	Path (L-)	Clinical Posting			Pharm (SDL-)	Lunch	Path (SGT-)		
Fri	Micro (SDL)	Clinical Posting			Path (SDL-)	Lunch	Pharm (SGT-)		
Sat	F.M.T (L/SDL-)	PANDEMIC Module	PANDEMIC Module	Pharm (L-)	Path (L-)	Lunch	Micro (SGT-)		
			3r d Saturday- Community Medicine- Family Adoption Program						

N.B.: 3rd Saturday 10-1 pm will be Family Adoption Program, Community Medicine

RAMA MEDICAL COLLEGE HOSPITAL & RESEARCH CENTRE, HAPUR

MASTER TIME TABLE MBBS PHASE II (BATCH 2023-2024)

DATE	DAY	8-9 am	9- 10am	10-11 am	11 am -12 noon	12-1 pm	1-2 pm	2-3 pm	3-4 pm	4-5 pm
9/16/2024	Mon	Path (L-1)PA 1.1 Pathology Introduction - 1	Clinical Posting			Micro (L-1) MI1.1 Introduction to Microbiology-I	Lunch	Pharma (SGT-,1,2) PH1.3 Enumerate and identify drug formulations and drug delivery		
9/17/2024	Tue	Phamra (L-1) PH1.1 Define and describe the principles of pharmacology and pharmacotherapeutics	Clinical Posting			Com. Med (SDL-1)CM 2.2 Describe the socio-cultural factors, family (types), its role in health and disease & demonstrate in a simulated environment the correct assessment of socio-economic status	Lunch	Micro SGT-1& 2: MI1.1 Introduction to Microbiology, Microscopy, Infectious agent		
9/18/2024	Wed	Micro (L-1) MI1.1 Introduction to Microbiology- II	Clinical Posting			Pharma (L-2) PH1.2 Describe the basis of Evidence based medicine and Therapeutic drug monitoring	Lunch	Path (SGT-01,02)PA 1.2,1.3 Pathology Introduction - 2		
9/19/2024	Thu	Path (L-2)PA 2.1,2.2 Cell Injury	Clinical Posting			O & G (L- 1)OG2.1 Anatomy of the female reproductive tract(VI-AN)	Lunch	Path (SGT-03,04)PA 2.1,2.2 Intracellular accumulation		
9/20/2024	Fri	Surgery (L-1) SU 14.1(VI-MI): Aseptic Techniques, sterilizatin and disinfection	Clinical Posting			Med (L- 1) Malaria-Pathophysiology & manifestations	Lunch	Pharma (SGT-,3,4) PH1.6 Describe principles of Pharmacovigilance & ADR reporting systems		
9/21/2024	Sat	Com. Med (L-1)CM 2.2 Describe the socio-cultural factors, family (types), its role in health and disease & demonstrate in a simulated environment the correct assessment of socio-economic status	Module 2.1: The foundations of communication - 2 (Pharma deptt)	Com. Med(FAP-1)Take history and conduct clinical examination of all family members (3 hours) 1			Lunch	Micro SGT-3 & 4: MI 1.2 Staining methods, Stool Examination-I		Sports/E CA
9/22/2024	SUNDAY									
9/23/2024	Mon	Path (L-3)PA 2.4 Necrosis	Clinical Posting			Micro (L-3) MI1.4, 1.5 (VI-SU) Sterilization- I	Lunch	Pharma (SGT-5,6) PH1.7 Define, identify and describe the management of		
9/24/2024	Tue	Pharma (L-3) PH1.4 Describe absorption, distribution, metabolism & excretion of drugs	Clinical Posting			Com. Med (SDL-2)CM 2.3 Describe and demonstrate in a simulated environment the assessment of barriers to good health and health seeking behavior	Lunch	Micro SGT-5 & 6: MI 1.2 Staining methods, Stool examination-II		
9/25/2024	Wed	Micro (L-3) MI1.4, 1.5 (VI-SU) Sterilization- II	Clinical Posting			Pharma (L-4) PH1.5 Describe general principles of mechanism of drug action	Lunch	Path (SGT-05,06)PA 2.5 Calcification and gangrene		
9/26/2024	Thu	Path (L-4)PA 2.7 Cellular aging and apoptosis	Clinical Posting			O & G (L-2) OG 2.1 Development of the female Reporductive Tract (VI-AN)	Lunch	Path (SGT-07,08)PA 2.6 Cellular adaptation		

9/27/2024	Fri	Surgery (L-2) SU 14.2(VI-MI): Surgical approaches, incisions and the use of appropriate instruments in General Surgery	Clinical Posting			Medicine L-2 IM 1.8: Common arrhythmias involved in heart failure (AF)	Lunch	Pharm (SGT- 7,8) PH1.8 Identify and describe the management of drug interactions	
9/28/2024	Sat	Com. Med (L-2)CM 2.3 Describe and demonstrate in a simulated environment the assessment of barriers to good health and health seeking behavior	Module 2.1: The foundations of communication - 2 (Pharma deptt)	Module 2.1: The foundations of communication - 2 (Pharma deptt)	Pharm (L-5) PH1.13 Describe mechanism of action, types, doses, side effects,	Path (L-5)PA 3.1 Amylodosis	Lunch	Micro SGT-7 & 8: MI 1.4, 1.5 (VI-SU) Sterilization & Disinfection-I	Sports/E CA
9/29/2024	SUNDAY								
9/30/2024	Mon	Path (L-6)PA 5.1 (VI SU) Wound repair & Healing, Regeneration	Clinical Posting			Micro (L-4) MI1.4, 1.5 (VI-SU) Disinfection- I	Lunch	Pharm (SGT-9,10) PH1.8 Identify and describe the management of drug interactions	
10/1/2024	Tue	Pharm (L-6) PH1.14 Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs	Clinical Posting			Com. Med (SDL-3)CM 2.4 Describe social psychology, community behaviour and community relationship and their impact on health and disease	Lunch	Micro SGT-9 & 10: MI 1.4, 1.5 (VI-SU) Sterilization & Disinfection-II	
10/2/2024	Wed	GH- Gandhi Jayanti							
10/3/2024	Thu	Path (L-7)PA 6.1 (VI IM) Edema	Clinical Posting			O & G (L- 3)OG 3.1 Physiology of Menstruation(VI-PY)	Lunch	Path (SGT-09,10)PA 2.8 Gross & M/E - Contracted Kidney, Testicular atrophy, Infarct - Kidney, Spleen	
10/4/2024	Fri	Surgery (L-3)SU 11.1: Preoperative assessment	Clinical Posting			Med (L- 3) IM 1.1, 1.2,1.3(VI-PY,PA): Heart Disease-Common Causes, their epidemiology, pathogenesis clinical features.	Lunch	Pharm (SGT-11,12) PH1.9 Describe nomenclature of drugs i.e. generic, branded drugs	
10/5/2024	Sat	Com. Med (L-3)CM 2.4 Describe social psychology, community behaviour and community relationship and their impact on health and disease	Module 2.1: The foundations of communication - 2 (Pharma deptt)	Module 2.1: The foundations of communication - 2 (Pharma deptt)	Pharm (L-7) PH1.15 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of skeletal muscle relaxants	Path (L-8)PA 6.2 Hyperemia & Congestion	Lunch	Micro SGT-11 & 12: MI 1.6 (HI- PH) Drug resistance & ABST-I	Sports/E CA
10/6/2024	SUNDAY								
10/7/2024	Mon	Path (L-9)PA 6.4 Hemostasis & Thrombosis	Clinical Posting			Micro (L-4) MI1.4, 1.5 (VI-SU) Disinfection- II	Lunch	Pharm (SGT-13,14) PH1.10 Describe parts of a correct, complete and legible	
10/8/2024	Tue	Pharm (L-8) PH1.15 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of skeletal muscle relaxants	Clinical Posting			Com. Med (SDL-4)CM 3.1 Describe the health hazards of air, water, noise, radiation	Lunch	Micro SGT-13 & 14: MI 1.6 (HI- PH) Drug resistance & ABST-II	
10/9/2024	Wed	Micro (L-5) MI1.6 (HI PH) Drug resistance & ABST- I	Clinical Posting			Pharm (L-)	Lunch	Path (SGT-11,12)PA 3.2 Gross & M/E - Amylodosis	
10/10/2024	Thu	Path (L-10)PA 6.5,6.6 Embolism, Ischemia & Infarction	Clinical Posting			O & G (L- 4)OG 3.1 Physiology of Conception(VI-PY)	Lunch	Path (SGT-13,14)PA6.3 (VI SU) Shock	

10/11/2024	Fri	Surgery (L-4) SU 14.3: Surgical wound closure and anastomosis(sutures,knots and needles)-materials and methods.	Clinical Posting			Med (L- 4) IM 1.2,1.3,1.4,1.5(VI-PY,PA): Heart Failure-Form-Clinical Features , Investigatio, Treatmnet, Treatmnet of Complications.	Lunch	Pharm (SGT-15,16) PH1.10 Describe parts of a correct, complete and legible generic prescription. Identify errors in prescription and correct appropriately	
10/12/2024	Sat	Com. Med (L-4)CM 3.1 (VI- General Medicine, ENT)Describe the health hazards of air, water, noise, radiation and pollution	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Pharm (L-9) PH1.15 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of skeletal muscle relaxants	Path (L-11)PA 7.1 C-1 Neoplasia 1	Lunch	Micro SGT-15 & 16: MI 2.1 (VI-IM & HI-PA) Diagnostic methods in Rheumatic fever-1	Sports/E CA
10/13/2024	SUNDAY								
10/14/2024	Mon	Path (L-12)PA 7.1 C-2 Neoplasia 2	Clinical Posting			Micro (L-5) MI1.6 (HI PH) Drug resistance & ABST- II	Lunch	Pharm (SGT-17,18) PH1.12 Calculate the dosage of drugs using appropriate	
10/15/2024	Tue	Pharm (L-10) PH1.15 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of skeletal muscle relaxants	Clinical Posting			Com. Med (SDL-5)CM 3.2 Describe concepts of safe and wholesome water, sanitary sources of water, water purification processes, water quality standards, concepts of water conservation and rainwater harvesting 1	Lunch	Micro SGT-17 & 18: MI 2.1 (VI-IM & HI-PA) Diagnostic methods in Rheumatic fever-2	
10/16/2024	Wed	Micro (L-32) MI 4.1 (VI-IM) Anaerobiasis	Clinical Posting			Pharm (L- 11) PH1.17 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of local anesthetics	Lunch	Path (SGT-15,16)PA 6.7 Gross & M/E CVC Liver, CVC Spleen, Heart Thrombus	
10/17/2024	Thu	Path (L-13)PA 7.2 Molecular Basis of Cancer	Clinical Posting			O & G (L- 5) OG 4.1 Fetal embryology (VI-AN)	Lunch	Path (SGT-17,18)PA 7.1.1 CL-2 Gross: FA, Ca Breast & M/E: FA, Ductal Ca Breast	
10/18/2024	Fri	Surgery (L-5) SU 6.1,6.2: Surgical Infections- etiology, pathogenesis, antibiotic plan	Clinical Posting			Med (L- 5) IM 1.2,1.3,1.4,1.5(VI-PY,PA): Hypertension-Cause, Classification, Clinical Manifestation.	Lunch	Pharm (SGT-19,20) PH1.12 Calculate the dosage of drugs using appropriate formulae for an individual patient, including children, elderly and patient with renal dysfunction.	
10/19/2024	Sat	Com. Med (L-5)CM 3.2 Describe concepts of safe and wholesome water, sanitary sources of water, water purification processes, water quality standards, concepts of water conservation and rainwater harvesting 1	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Com. Med(FAP-2)Take history and conduct clinical examination of all family members (3 hours) 2			Lunch	Micro SGT-19 & 20: MI 2.3 (VI-IM & HI-PA) Diagnostic methods in Endocarditis	Sports/E CA

10/20/2024	SUNDAY								
10/21/2024	Mon	Path (L-14)PA 7.3,7.4 Paraneoplastic syndromes,Carcinogenesis	Clinical Posting			Micro (L-49) MI 8.9, 8.10, 8.11 Sample Collection	Lunch	Pharm (SGT-21,22) PH1.12 Calculate the dosage of drugs using appropriate formulae for an	
10/22/2024	Tue	Pharm (L-12) PH1.17 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of local anesthetics	Clinical Posting			Com. Med (SDL-6)CM 3.2 Describe concepts of safe and wholesome water, sanitary sources of water, water purification processes, water quality standards, concepts of water conservation and rainwater harvesting 2	Lunch	Micro SGT-21& 22: MI 2.4 (VI-IM & HI-PA) Diagnostic methods of microbial agents causing anemia-I	
10/23/2024	Wed	Micro (L-50) MI 8.12 Lab practices	Clinical Posting			Pharm (L- 13) PH1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anaesthetics, and preanesthetic medications	Lunch	Path (SGT-19,20)PA 7.1.1 C-3 Gross: Lipoma, Leiomyoma, Dermoid Cyst & M/E: Lipoma, Leiomyoma, Neurilemmoma, Teratoma	
10/24/2024	Thu	Path (L-15)PA 4.1 (VI SU) Cellular and vascular events, Acute inflammation	Clinical Posting			O & G (L- 6)OG 4.1 Anatomy and physiology of placenta (VI-AN)	Lunch	Path (SGT-21,22)PA 7.1.1 C-4 Gross: SCC Cervix, SCC Penis & M/E: SCC, BCC	
10/25/2024	Fri	Surgery (L-6) SU 5.1,5.3: (VI-PA): Wound- Types, Clinical features, Factors affecting healing Management.	Clinical Posting			Med (L- 6) IM 25.1, 25.2, 25.3 (VI-MI, CM): Zoonotic Diseases- Leptospirosis- Clinical features, Management	Lunch	Pharm (SGT- 23 & 24) PH1.12 Calculate the dosage of drugs using appropriate formulae for an individual patient, including children, elderly and patient with renal	
10/26/2024	Sat	Com. Med (L-6)CM 3.2 Describe concepts of safe and wholesome water, sanitary sources of water, water purification processes, water quality standards, concepts of water conservation and rainwater harvesting 2	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Pharm (L- 14) PH1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anaesthetics, and preanesthetic medications	Path (L-16)PA 4.2 (VI SU) Mediators of Acute inflammation	Lunch	Micro SGT-23 & 24: MI 2.4 (VI-IM & HI-PA) Diagnostic methods of microbial agents causing anemia-II	Sports/E CA
10/27/2024	SUNDAY								
10/28/2024	Mon	Path (L-17)PA 4.3 Chronic Inflammation	Clinical Posting			Micro (L-51) MI 8.15 Interpretation of results- I	Lunch	Pharm (SGT- 25 & 26) PH2.1 Demonstrate understanding of the use	
10/29/2024	Tue	Pharm (L- 15) PH1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anaesthetics, and preanesthetic medications	Clinical Posting			Com. Med (SDL-7)CM 3.3 Describe the aetiology and basis of water borne diseases /jaundice/hepatitis/ diarrheal diseases 1	Lunch	Micro SGT-25 & 26: MI 2.5 (VI-IM & HI-PA) Diagnostic methods of microbial agents causing Kala Azar & Filaria-I	

10/30/2024	Wed	Micro (L-51) MI 8.15 Interpretation of results- II	Clinical Posting			Pharm (L- 16) PH1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anaesthetics, and preanesthetic medications	Lunch	Path (SGT-23,24)PA 7.1.1 C-5 Gross: Melonoma, Rodent Ulcer & M/E: Melonoma, BCC	Sports/E CA	
10/31/2024	Thu	GH- Deepawali								
11/1/2024	Fri	GH- Deepawali								
11/2/2024	Sat	GH- Deepawali								
11/3/2024	SUNDAY									
11/4/2024	Mon	Path (L-18)PA 7.5 (HI MI) Immunology basic with emphasis on immune response to cancer	Clinical Posting			Micro (L-6) MI1.9 (VI-PE) Immunity and Vaccines	Lunch	Pharm (SGT- 27 & 28)PH2.1 Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid)		
11/5/2024	Tue	Pharm (L- 17) PH1.20 Describe the effects of acute and chronic ethanol intake	Clinical Posting			Com. Med (SDL-8)CM 3.3 Describe the aetiology and basis of water borne diseases /jaundice/hepatitis/ diarrheal diseases 2	Lunch	Micro SGT-27 & 28: MI 2.5 (VI-IM & HI- PA) Diagnostic methods of microbial agents causing Kala Azar & Filaria-II		
11/6/2024	Wed	Micro (L-7) MI1.7 (HI-PA) Immunological mechanisms - Antigen	Clinical Posting			Pharm (L- 18) PH1.21 Describe the symptoms and management of methanol and ethanol poisonings	Lunch	Path (SGT-25,26)PA 7.1.1 PA 7.1.1 C-6 Gross & M/E: AdenoCa- Endometrium, Stomach,Colon		
11/7/2024	Thu	Path (L-19)PA 9.1 (VI PE)(HI MI) Immunity	Clinical Posting			O & G (L- 7)OG 6.1 Pregnancy- clinical features, DD Investigation	Lunch	Path (SGT-27,28)PA 4.4 C-1 Gross & M/E Lobar Pnuemonia, Acute appendicitis		
11/8/2024	Fri	Surgery (L-7) SU 1.1,1.2: (VI- PY,BI): Injury- Homeostasis, metabolic changes, Factors	Clinical Posting			IM 11.1,11.2, 11.3, 11.4: Diabetes Mellitus Classification, Patho., risk factors & Mgt.	Lunch	Pharm (SGT- 29 & 30) PH2.2 Prepare oral rehydration solution from ORS packet and explain its use		
11/9/2024	Sat	Com. Med (L-7)CM 3.2 Describe concepts of safe and wholesome water, sanitary sources of water, water purification processes, water quality standards, concepts of water conservation and rainwater harvesting 3	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Pharm (L-18.1 PH1.21 Describe the symptoms and management of methanol and ethanol)	Path (L-20)PA 9.3 (HI MI) HLA & Transplant rejection	Lunch	Micro SGT 55 & 56: MI 6.1,6.2 (VI-IM) Diagnostic methods in URTI & LRTI-I	Sports/E CA	
11/10/2024	SUNDAY									
11/11/2024	Mon	Path (L-21)PA 9.5 (VI IM) SLE	Clinical Posting			Micro (L-8) MI1.7 (HI-PA) Immunological mechanisms - Antibodies	Lunch	Pharm (SGT- 31 & 32) PH2.2 Prepare oral rehydration solution from ORS packet and explain its		

11/12/2024	Tue	Pharm (L- 19) PH1.24 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs affecting renal systems including diuretics, antidiuretics- vasopressin and analogues	Clinical Posting	Com. Med (SDL-9)CM 3.3 Describe the aetiology and basis of water borne diseases /jaundice/hepatitis/ diarrheal diseases	Lunch	Micro SGT 57 & 58: MI 6.1,6.2 (VI-IM) Diagnostic methods in URTI & LRTI-II	
11/13/2024	Wed	Micro (L-9) MI1.8 (VI-PE & HI-PA) Immune response - I	Clinical Posting	Pharm (L- 20) PH1.24 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs affecting renal systems including diuretics, antidiuretics- vasopressin and analogues	Lunch	Path (SGT-29,30)PA 4.4 C-2 Gross & M/E FB Granuloma, Chronic Cholecystitis	
11/14/2024	Thu	Path (L-22)PA 11.1 (VI PE) Pathogenesis of common cytogetic abnormality & Mutation in childhood	Clinical Posting	O & G (L- 8)OG 7.1: Physiological changes during Pregnancy (VI-PY)	Lunch	Path (SGT-31,32)PA 4.4 C-3 Gross & M/E TB Lung and LN	
11/15/2024	Fri	GH- Guru Nanak Jayanti					
11/16/2024	Sat	Com. Med (L-8)CM 3.3 (VI-Microbiology, General medicine, Pediatrics)Describe the aetiology and basis of water borne diseases /jaundice/hepatitis/ diarrheal diseases	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Com. Med(FAP- 3)Organize health check-up and coordinate treatment of adopted family under overall guidance of mentor (3 hours) 1	Lunch	Micro SGT-59 & 60: MI 6.3 (VI-IM); LRTI-I	Sports/E CA
11/17/2024		SUNDAY					
11/18/2024	Mon	Path (L-23)PA 11.2(VI PE) Pathology of tumor/ Tumour like condition in infancy & Childhood	Clinical Posting	Micro (L-10) MI1.8 (VI-PE & HI-PA) Immune response - II	Lunch	Pharm (SGT- 33 & 34) PH2.3 Demonstrate the appropriate setting up of an intravenous drip in a simulated environment	
11/19/2024	Tue	Pharm (L- 21) Integration (1) PY3.5 Discuss the Action of neuro-Muscular blocking agents.	Clinical Posting	Com. Med (SDL-10) CM 3.5 Describe the standards of housing and the effect of housing on health 1	Lunch	Micro SGT- 61 & 62: MI 6.3 (VI-IM); LRTI-II	
11/20/2024	Wed	Micro (L-11) MI1.10 (VI-PE) Antigen antibody reaction - I	Clinical Posting	Pharm (L-22) PH1.25 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets, fibrinolytics, plasma expanders	Lunch	Path (SGT-33,34)PA 4.4 C-4 Gross & M/E Peptic Ulcer, Trophic leg Ulcer, Ulcer with Granulation tissue	
11/21/2024	Thu	Path (L-24) PA 27.1(VI IM) Arteriosclerosis	Clinical Posting	O & G (L- 9)OG 8.2 Obstetric history taking	Lunch	Path (SGT-35,36)PA 8.1, 8.2 (VI SU) Cytology Basic inc Exfoliative Cytology	

11/22/2024	Fri	Surgery (L-8) SU 17.7: Soft Tissue Injuries- Clinical features, Investigations, Management	Clinical Posting			Med (L- 8) IM 25.1, 25.2, 25.3 (VI-MI, CM): Zoonotic Diseases- Rabies- Clinical features, Management	Lunch	Pharm (SGT- 35 & 36) PH2.3 Demonstrate the appropriate setting up of an intravenous drip in a simulated environment	
11/23/2024	Sat	Com. Med (L-9)CM 3.4 Describe the concept of solid waste, human excreta and sewage disposal	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (Pathology deptt)	Pharm (L-23) PH1.26 Describe mechanisms of action, types, doses, side effects, indications and contraindications of the drugs modulating the reninangiotensin and aldosterone system	Path (L-25)PA 27.4 (VI IM)(HI MI) Rheumatic Fever	Lunch	Micro SGT 53 & 54: MI 5.3 (VI-IM, PE) Meningitis	Sports/E CA
11/24/2024	SUNDAY								
11/25/2024	Mon	Path (L-26) PA 27.5 (VI IM) Ischemic Heart Ds	Clinical Posting			Micro (L-12) MI1.10 (VI-PE) Antigen antibody reaction - II	Lunch	Pharm (SGT-37,38) PH2.4 Demonstrate the correct method of calculation of drug dosage in	
11/26/2024	Tue	Pharm (L-24) PH1.27 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugs and drugs used in shock	Clinical Posting			Com. Med (SDL-11) CM 3.5 Describe the standards of housing and the effect of housing on health 2	Lunch	Micro SGT-63 & 64: MI 7.1 (VI-SU) Diagnostic methods in Genito urinary tract Infections-I	
11/27/2024	Wed	Micro (L-13) MI1.10 (VI-PE) Hypersensitivity - I	Clinical Posting			Pharm (L-25) PH1.27 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugs and drugs used in shock	Lunch	Path (SGT-37,38)PA 8.3 FNAC & Staining with Cytosmear: Ca Cervix, FA, Ca Breast, Trichompnas Vaginilis	
11/28/2024	Thu	Path (L-27) PA 27.9, 27.10 (VI IM, PY VI IM HI MI) Syphllis In CVS,Cardiomyopathy	Clinical Posting			O & G (L- 10)OG 8.1 Antenatal Care (VI-CM)	Lunch	Path (SGT-39,40)PA 9.2 (HI MI) Hypersensitivity Reactions	
11/29/2024	Fri	Surgery (L-9) SU 18.1: Cutaneous and subcutaneous infections-pathogenesis, clinical features and Management	Clinical Posting			Med (L- 9) IM 25.1, 25.2, 25.3 (VI-MI, CM): Zoonotic Diseases-Tetanus- Clinical features, Management	Lunch	Pharm (SGT-39,40)PH2.4 Demonstrate the correct method of calculation of drug dosage in patients including those used in special situations	

11/30/2024	Sat	Com. Med (L-10) CM 3.5 Describe the standards of housing and the effect of housing on health 1	Module 2.2 The foundations of bioethics (Microbiology deptt)	Module 2.2 The foundations of bioethics (Microbiology deptt)	Pharm (L-26) PH1.28 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in ischemic heart disease (stable, unstable angina and myocardial infarction), peripheral vascular disease	Path (L-28)PA 13.1(VI IM) Hematopoiesis & EMH	Lunch	Micro SGT-65 & 66: MI 7.1 (VI-SU) Diagnostic methods in Genito urinary tract infections-II	Sports/E CA
12/1/2024	SUNDAY								
12/2/2024	Mon	Path (L-29)PA 13.3,13.4 (VI IM) Anemia-Classification and approach to investigation	Clinical Posting			Micro (L-14) MI1.10 (VI-PE) Hypersensitivity - II	Lunch	Pharm (SGT-41,42) PH3.1 Write a rational, correct and legible generic prescription for a given	
12/3/2024	Tue	Pharm (L-27) Integration (2) MI1.6 Describe the mechanisms of drug Resistance, methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy.	Clinical Posting			Com. Med (SDL-12) CM 3.6 Describe the role of vectors in the causation of diseases. Also discuss National Vector Borne disease Control Program 1	Lunch	Micro SGT-67 & 68: MI 7.2 (VI-DR, OG) Diagnostic methods in STD	
12/4/2024	Wed	Micro (L-15) MI 1.11 Immunodeficiency disease, Complement system and Autoimmunity	Clinical Posting			Pharm (L-28) PH1.29 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure	Lunch	Path (SGT-41,42)PA 9.3, 9.4 (VI IM) Autoimmune disorder, HLA system	
12/5/2024	Thu	Path (L-30)PA 14.1,14.2(VI IM, BI) Microcytic anemia- IDA- Iron metabolism, Patho, other DD	Clinical Posting			O & G (L- 11)OG 8.7 Vaccinations during pregnancy	Lunch	Path (SGT-43,44)PA 9.6,9.7 (HI MI) (VI IM) HIV/AIDS & other autoimmune disorder	
12/6/2024	Fri	Surgery (L-10) SU 17.3: Mass Causalities- Management	Clinical Posting			Med (L- 10) IM 14.1, 14.2, 14.3: Obesity- Causes, Risk factors, monogenic forms.	Lunch	Pharm (SGT- 43,44) PH3.1 Write a rational, correct and legible generic prescription for a given condition and communicate the same to	
12/7/2024	Sat	Com. Med (L-11) CM 3.5 Describe the standards of housing and the effect of housing on health 2	Module 2.3: Health care as a right (Microbiology deptt)	Module 2.3: Health care as a right (Microbiology deptt)	Pharm (L-29) MI3.6 Integration (3) Describe the etio-pethogenesis of acid Peptic Diseasee (APD) and the cinical course. Discuss the diagnosis and management of the causative agent of APD.	Path (L-31)PA 15.1,15.2,15.4(VI IM, BI) Macrocytic anemia	Lunch	Micro SGT-69 & 70: MI 7.3 (VI-IM); Diagnostic methods in UTI-I	Sports/E CA
12/8/2024	SUNDAY								
12/9/2024	Mon	Path (L-32)PA 16.1,16.2(VI IM, BI) Hemolytic anemia	Clinical Posting			Micro (L-16) MI 1.11 Transplant & Cancer immunology	Lunch	Pharm (SGT-45,46) PH3.2 Perform and interpret a critical appraisal (audit) of a given	

12/10/2024	Tue	Pharm (L-30) PH1.30 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the antiarrhythmics	Clinical Posting			Com. Med (SDL-13)CM 3.6 Describe the role of vectors in the causation of diseases. Also discuss National Vector Borne disease Control Program 2	Lunch	Micro SGT-71 & 72: MI 7.3 (VI-IM); Diagnostic methods in UTI-II	
12/11/2024	Wed	Micro (L-17) MI 2.1 (VI-IM & HI-PA) Rheumatic fever	Clinical Posting			Pharm (L-31) PH1.30 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the antiarrhythmics	Lunch	Path (SGT-45,46)PA 10.1,10.2 (VI IM) (HI MI) Malaria, Cysticercosis	
12/12/2024	Thu	Path (L-33)PA 16.3 (VI IM, BI) Sickle Cell anemia & Thalassemia	Clinical Posting			O & G (L- 12)OG 8.8 USG & other investigations during antenatal period	Lunch	Path (SGT-47,48)PA 10.3,10.4 (VI IM) (HI MI) Leprosy & other Microbial disease	
12/13/2024	Fri	Surgery (L-11) SU 27.5,27.6: Venous system & Varicose Veins- Clinical features, Investigation, Management	Clinical Posting			Med (L- 11) IM 24.1, 24.2, 24.3 : Geriatric Problems- Common Causes, aetiopathogenesis, clinical presentation of common problems.	Lunch	Pharm (SGT-47,48) PH3.2 Perform and interpret a critical appraisal (audit) of a given prescription	
12/14/2024	Sat	Com. Med (L-12)CM 3.6 (VI-Microbiology) Describe the role of vectors in the causation of diseases. Also discuss National Vector Borne disease Control Program	Module 2.8: What does it mean to be family member of a sick patient? (Pharma deptt)	Module 2.8: What does it mean to be family member of a sick patient? (Pharma deptt)	Pharm (L-)	Path (L-34)PA 16.4 (VI IM, BI)Acquired Hemolytic anemias	Lunch	Micro SGT-29 & 30: MI 2.6 (VI-IM) Hookworm, Roundworm -I	Sports/E CA
12/15/2024	SUNDAY								
12/16/2024	Mon	Path (L-35)PA 17.1,17.2 (VI IM) Aplastic anemias	Clinical Posting			Micro (L-18) MI 2.2 (VI-IM & HI-PA) Infective endocarditis	Lunch	Pharm (SGT-49,50) PH3.2 Perform and interpret a critical appraisal (audit) of a given	
12/17/2024	Tue	Pharm (L-32) PH1.30 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the antiarrhythmics	Clinical Posting			Com. Med (SDL-14)CM 3.7 Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures 1	Lunch	Micro SGT-31 & 32: MI 2.6 (VI-IM) Hookworm, Roundworm-II	
12/18/2024	Wed	Micro (L-19) MI 2.4 (VI-IM & HI-PA) Anemia	Clinical Posting			Pharm (L-33)PH1.31 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in the management of dyslipidemias	Lunch	Path (SGT-49,50)PA 12.1 (HI CM) Effect of Environmental Pollution, Tobacco and Alcohol on Health	
12/19/2024	Thu	Path (L-36)PA 18.2 C-1 Acute leukemia	Clinical Posting			O & G (L-13)OG 19.1 Physiology of puerperium	Lunch	Path (SGT-51,52)PA 11.3 Common Storage Disorder	

12/20/2024	Fri	Surgery (L-12) SU 28.5,28.6: Lymphatic system & Diseases- Pathophysiology, Investigation & Management.	Clinical Posting			Med (L- 12) IM 6.2, 6.3, 6.4 (VI-MI): HIV/AIDS-Classification, CDC Count and Opportunistic Infections, Malignant, Skin & Oral Lesions	Lunch	Pharm (SGT-51,52) PH3.3 Perform a critical evaluation of the drug promotional literature			
12/21/2024	Sat	Com. Med (L-13)CM 3.7 (VI-Microbiology) Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures 1	Module 2.8: What does it mean to be family member of a sick patient? (Pharma deptt)	Com. Med(FAP-4)Organize health check-up and coordinate treatment of adopted family under overall guidance of mentor (3hours) 2			Lunch	Micro SGT-35 &36: MI 3.1, 3.2 (VI-IM & PE, HI-PA) Diagnostic methods in Diarrhea & Dysentery-I		Sports/E CA	
12/22/2024	SUNDAY										
12/23/2024	Mon	Path (L-37)PA 18.2 C-2 Chronic leukemia	Clinical Posting			Micro (L-20) MI 2.5 (VI-IM & HI-PA) Kala Azar	Lunch	Pharm (SGT-53,54) PH3.3 Perform a critical evaluation of the drug			
12/24/2024	Tue	Pharm (L-34) PH1.32 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in bronchial asthma and COPD	Clinical Posting			Com. Med (SDL-15)CM 3.7 Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures 2	Lunch	Micro SGT-37 &38: MI 3.1, 3.2 (VI-IM & PE, HI-PA) Diagnostic methods in Diarrhea & Dysentery-II			
12/25/2024	Wed	GH- Christmas									
12/26/2024	Thu	Winter Vacations									
12/27/2024	Fri	Winter Vacations									
12/28/2024	Sat	Winter Vacations									Sports/E CA
12/29/2024	SUNDAY										
12/30/2024	Mon	Winter Vacations									
12/31/2024	Tue	Winter Vacations									
1/1/2025	Wed	GH- New Year									
1/2/2025	Thu	Path (L-38)PA 19.1,19.2 (VI SU) Lymphadenopathy, TB LN	Clinical Posting			O & G (L- 14)OG 17.1 Physiology of lactation	Lunch	Path (SGT-53,54)PA 12.2,12.3 (VI IM VI PE,BI) PEM,Obesity			
1/3/2025	Fri	Surgery (L-13) SU 28.1, 28.2: Hernia-Types, Clinical features, investigations & Management.	Clinical Posting			Med (L- 13) Fever of unknown origin(FUO)- pathophysiology, etiology & clinical manifestations	Lunch	Pharm (SGT-55,56) PH3.4 To recognise and report an adverse drug reaction			
1/4/2025	Sat	Com. Med (L-14)CM 3.7 Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures 2	Module 2.8: What does it mean to be family member of a sick patient? (Pharma deptt)	Module 2.8: What does it mean to be family member of a sick patient? (Pharma deptt)	Pharm (L-35) PH1.32 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in bronchial asthma and COPD	Path (L-39)PA 19.4 (VI SU) C-1 Hodgkin Lymphoma	Lunch	Micro SGT-39: MI 3.3, 3.4 (VI-IM, HI-PA) Diagnostic methods in Enteric fever-I-Part 1	Micro SGT-40: MI 3.3, 3.4 (VI-IM, HI-PA) Diagnostic methods in Enteric fever-II-Part 2	Sports/E CA	
1/5/2025	SUNDAY										
1/6/2025	Mon	Term I									
1/7/2025	Tue	Term I									
1/8/2025	Wed	Term I									
1/9/2025	Thu	Term I									

1/10/2025	Fri	Term I						
1/11/2025	Sat	Term I						
1/12/2025		SUNDAY						
1/13/2025	Mon	Term I						
1/14/2025	Tue	Term I						
1/15/2025	Wed	Micro (L-21) MI 2.5 (VI-IM & HI-PA) Filaria	Clinical Posting		Pharm (L-36) PH1.33 Describe the mechanism of action, types, doses, side effects, indications and contraindications of the drugs used in cough (antitussives, expectorants/ mucolytics)	Lunch	Path (SGT-55,56)PA27.2, 27.3(VI IM, PY) Aortic Aneurism, Heart Failure	
1/16/2025	Thu	Path (L-40)PA 19.4(VI SU) C-2 Non Hodgkin lymphoma,HL vs NHL	Clinical Posting		O & G (L- 15)OG23.1, 32.1 PUBERTY & Menopause-Physiology and their disorders	Lunch	Path (SGT-57,58)PA 27.6 27.7(VI IM) (HI MI) Infective endocarditis, Pericarditis	
1/17/2025	Fri	Surgery (L-14) SU 3.1, 3.2 (VI-PA): Blood Transfusion- Indications, components used, complications.	Clinical Posting		Med (L- 14) IM 11.5, 11.6 (VI-PA): Diabetes Mellitus-Complications & its Management	Lunch	Pharm (SGT-57,58) PH3.4 To recognise and report an adverse drug reaction	
1/18/2025	Sat	Com. Med (L-15) CM 3.8 (VI- Pharmacology) Describe the mode of action, application cycle of commonly used insecticides and rodenticides	Module 2.8: What does it mean to be family member of a sick patient? (Pharma deptt)	Com. Med(FAP- 5) Organize health check-up and coordinate treatment of adopted family under overall guidance		Lunch	Micro SGT-41 & 42: MI 3.3, 3.4 (VI-IM, HI-PA) Diagnostic methods in Enteric fever-I-Part I & II	Sports/E CA
1/19/2025		SUNDAY						
1/20/2025	Mon	Path (L-41)PA 21.1 Hemostasis	Clinical Posting		Micro (L-36) MI 6.1, 6.2, 6.3 (VI- IM) URTI	Lunch	Pharm (SGT-59,60) PH3.4 To recognise and report an adverse drug reaction	
1/21/2025	Tue	Pharm (L-37) PH1.34 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease and GERD 2. Antiemetics and prokinetics 3. Antidiarrhoeals 4 . Laxatives 5. Inflammatory Bowel Disease 6. Irritable Bowel Disorders, biliary and pancreatic diseases	Clinical Posting		Com. Med (SDL-16) CM 3.8 Describe the mode of action, application cycle of commonly used insecticides and rodenticides	Lunch	Micro SGT-43 & 44: MI 3.5 (VI-IM & HI-PA) Diagnostic methods in Food Poisoning-I	

1/22/2025	Wed	Micro (L-37) MI 6.1, 6.2, 6.3 (VI-IM) LRTI	Clinical Posting			Pharm (L-38) PH1.35 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in hematological disorders like: 1. Drugs used in anemias 2. Colony Stimulating factors	Lunch	Path (SGT-59,60)PA 27.8(VI IM, PY) Cardiac Fuction test in acute coronary sndrome	
1/23/2025	Thu	Path (L-42)PA 21.2(VI PE) Vascular and platelets disorder-ITP, Hemophillia	Clinical Posting			O & G (L- 16)OG 9.1 Abortions- Classification, definition, etiology	Lunch	Path (SGT-61,62)PA 13.2 (VI IM) Anticoagulants in Hematology and vacutainers	
1/24/2025	Fri	Surgery(L-15) SU 4.1, 4.2 (VI-PY): Burns-Types, clinical features, pathophysiology, treatment.	Clinical Posting			Med (L- 15) Pneumonia- types, etiology, pathogenesis, Clinical Features, Complication.	Lunch	Pharm (SGT-61,62) PH3.6 Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs	
1/25/2025	Sat	Com. Med (L-16)- Feedback/Assessment	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (Microbiology deptt)	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (Microbiology deptt)	Pharm (L-39) PH1.35 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in hematological disorders like: 1. Drugs used in anemias 2. Colony Stimulating factors	Path (L-43)PA 21.3 (VI IM) Diffrentiate Platlet from clotting disorder based on clinical and hematological features	Lunch	Micro SGT-45 & 46: MI 3.5 (VI-IM & HI-PA) Diagnostic methods in Food Poisoning-II	Sports/E CA
1/26/2025	SUNDAY	GH- Republic day							
1/27/2025	Mon	Path (L-44)PA 21.4,21.5 (VI IM) DIC, Vit K def	Clinical Posting			Micro (L-35) MI 5.1 (VI-IM,PE& HI-PA) Meningitis	Lunch	Pharm (SGT-63,64) PH3.6 Demonstrate how to optimize interaction with	
1/28/2025	Tue	Pharm (L-40) PH1.36 Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)	Clinical Posting			F.M.T SGT-1 FM1.5,1.6,1.7 Court procedures Dying Declaration	Lunch	Micro SGT-47& 48: MI 3.6 (VI-IM, HI-PH & PA) Diagnostic methods in Acid peptic disease	
1/29/2025	Wed	Micro (L-39) MI 5. 2 (VI-IM,PE & HI-PA) Encephalitis	Clinical Posting			Pharm (L-41) PH1.38 Describe the mechanism of action, types, doses, side effects, indications and contraindications of corticosteroids	Lunch	Path (SGT-63,64)PA 13.5 C-1 Hb Estimation	
1/30/2025	Thu	Path (L-45) PA 26.1,26.2(HI MI) Pnuemonia, Lung abcess	Clinical Posting			O & G (L- 17)OG 13.4 stages of normal labor-demonstrate	Lunch	Path (SGT-65,66)PA 13.5 C-2 RBC Count, RBC indices & Reticulocyte count	

1/31/2025	Fri	Surgery(L-16) SU 28.8: Peptic Ulcer- clinical features, investigations and management	Clinical Posting			Med (L- 16) Bronchial Asthma- etiology, pathogenesis, Clinical Features, Complication.	Lunch	Pharm (SGT-65,66) PH3.7 Prepare a list of essential medicines for a healthcare facility	
2/1/2025	Sat	F.M.T L-1: FM 1.1 & 1.2 Definitions, History of FM	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (Microbiology deptt)	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (Microbiology deptt)	Pharm (L-42) PH1.38 Describe the mechanism of action, types, doses, side effects, indications and contraindications of corticosteroids	Path (L-46) PA 26.3 (HI MI) (VI PI, IM) Obstructive airway disease, Bronchiactasis	Lunch	Micro SGT-49 & 50: MI 3.7, 3.8 VI-IM, HI-PA) Diagnostic methods in Viral Hepatitis-I	Sports/E CA
2/2/2025	SUNDAY								
2/3/2025	Mon	Path (L-47) PA 35.2 (VI PE) CNS tumours	Clinical Posting			Micro (L-38) MI 7.1 (VI-SU) Genito urinary tract infections	Lunch	Pharm (SGT-67,68) PH3.7 Prepare a list of essential medicines for a healthcare facility	
2/4/2025	Tue	Pharm (L-43) PH1.39 Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception	Clinical Posting			F.M.T SGT-2 : FM1.9 (VI- RD, SU, IM, PE): Documentation, case records, accident register	Lunch	Micro SGT-51 & 52: MI 3.7, 3.8 VI-IM, HI-PA) Diagnostic methods in Viral hepatitis-II	
2/5/2025	Wed	Micro (L-40) MI 7.2 (VI-DR, OG) STD	Clinical Posting			Pharm (L-44) PH1.40 Describe mechanism of action, types, doses, side effects, indications and contraindications of 1. Drugs used in the treatment of infertility, and 2. Drugs used in erectile dysfunction	Lunch	Path (SGT-67,68)PA 13.5 C-3 WBC count & Platelet count	
2/6/2025	Thu	Path (L-48) PA 28.2, 28.3, 28.4(VI IM) Renal Failure	Clinical Posting			O & G (L- 18)OG 13.5 conduct of normal delivery- Observe/assist	Lunch	Path (SGT-69,70)PA 14.3 CBC & PS interpretation of microcytic anemia	
2/7/2025	Fri	Surgery (L-17) SU 28.15: Appendix Diseases-Clinical features, complication, Investigations & Management.	Clinical Posting			Med (L- 17) IM 11.5, 11..6 (VI-PA): Diabetes Mellitus- Complications & its Management	Lunch	Pharm (SGT-69,70) PH3.8 Communicate effectively with a patient on the proper use of prescribed medication	
2/8/2025	Sat	F.M.T L 2: FM1.3 & 1.4, 1.8 Legal procedures Cr.PC IPC Inquest Courts in India	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (Microbiology deptt)	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (Microbiology deptt)	Pharm (L-45) PH1.41 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of uterine relaxants and stimulants	Path (L-49) PA 28.5 (VI IM, PY) Glomerular disease	Lunch	Micro SGT-33 & 34; MI 2.7 (VI-IM, HI-PA) Diagnostic methods in HIV	Sports/E CA
2/9/2025	SUNDAY								

2/10/2025	Mon	Path (L-50) PA 28.6,28.7(VI IM) IgA Nephropathy, glomerular manifestations of systemic disease	Clinical Posting			Micro (L-41) MI 7.3 (VI-IM) UTI	Lunch	Pharm (SGT-71,72) PH3.8 Communicate effectively with a patient on the proper use of prescribed medication	
2/11/2025	Tue	Pharm (L-46) PH1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program	Clinical Posting			F.M.T SGT-3 : FM1.9 (VI- RD, SU, IM, PE): Wound, drunkenness, fitness certificate	Lunch	Micro SGT-73 & 74: MI 8.1(VI-IM) Diagnostic methods in Zoonotic Diseases	
2/12/2025	Wed	Micro (L-22) MI 2.6 (VI-IM) Hookworm	Clinical Posting			Pharm (L-47) PH1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program	Lunch	Path (SGT-71,72)PA 16.5 (VI IM) Describe PS in different Hemolytic anemias	
2/13/2025	Thu	Path (L-51) PA 28.8, 28.9(VI IM) ATN	Clinical Posting			O & G (L-19)OG 16.1 PPH-causes, diagnosis, prevention	Lunch	Path (SGT-73,74)PA 16.6 CBC & PS interpretation of Hemolytic anemia	
2/14/2025	Fri	Surgery (L-18) SU 29.3: UTI- Clinical features, Investigations and management.	Clinical Posting			Med (L- 18) IM 12.1, 12.2, 12.3, 12.4 (VI- PY, PA): Thyroid dysfn.- Pathogenesis, CF	Lunch	Pharm (SGT-73,74) PH4.1 Administer drugs through various routes in a simulated environment using mannequins	
2/15/2025	Sat	F.M.T SDI-1 FM1.3 & 1.4, 1.8: Legal procedures Cr.PC IPC Inquest Courts in India	Module 2.4: Working in a health care team (Pathology deptt)	Com. Med(FAP-6) Maintain communication & follow up of remedial measures (3 hours) 1			Lunch	Micro SGT-75 & 76: MI 8.4 (VI-IM, CM) Diagnostic methods in Emerging Infections-I	Sports/ECA
2/16/2025	SUNDAY								
2/17/2025	Mon	Path (L-52) PA 28.12 (VI IM, PE) Cystic Ds of Kidney	Clinical Posting			Micro (L-23) MI 2.6 (VI-IM) Roundworm	Lunch	Pharm (SGT-75,76) PH4.1 Administer drugs through various routes in a	
2/18/2025	Tue	Pharm (L-48) PH1.44 Describe the first line antitubercular dugs, their mechanisms of action, side effects and doses.	Clinical Posting			F.M.T SGT- 4 FM2.8,2.9,2.10 PM Changes, Estimation, of time since death	Lunch	Micro SGT-77 & 78: MI 8.4 (VI-IM, CM) Diagnostic methods in Emerging Infections-II	
2/19/2025	Wed	Micro (L-26) MI 3.1, 3.2 (VI-IM & PE, HI-PA) Diarrhea & Dysentery	Clinical Posting			Pharm (L-49) PH1.44 Describe the first line antitubercular dugs, their mechanisms of action, side effects and doses.	Lunch	Path (SGT-75,76)PA 18.1 Leucocytic disorder-intro, Leukocytosis, leukopenial leukocytosis, Leukemoid reaction, Benign vs malignant	
2/20/2025	Thu	Path (L-53) PA 28.13,28.15(VI IM VI SU) Thrombotic microangiopathies, Renal stone, obstructive uropathy	Clinical Posting			O & G (L-20)OOG 22.1, 22.2 Vaginal discharge- normal and abnormal- etiology	Lunch	Path (SGT-77,78)PA 18.2.1 C-1 AML & ALL	
2/21/2025	Fri	Surg (L)- Assessment/Feedback	Clinical Posting			Med (L- 19) IM 13.1, 13.2, 13.3, 13.4, 13.5 (VI-BI, PA): Cancer- Common malignancies, risk factors, CF & Mgt.	Lunch	Pharm (SGT-77,78) Pharma Practical Revision	
2/22/2025	Sat	F.M.T L 3: FM 1.10,1.11Cause of death, ICD ,death certificate (L)	Module 2.4: Working in a health care team (Pathology deptt)	Module 2.4: Working in a health care team (Pathology deptt)	Pharm (L-50) PH1.44 Describe the first line antitubercular dugs, their mechanisms of action, side effects and doses.	Path (L-54) PA 29.1(VI SU) Testicular tumours	Lunch	Micro SGT-79 & 80: MI8.5 ((VI-IM, CM) Health care infections -I	Sports/ECA
2/23/2025	SUNDAY								

2/24/2025	Mon	Path (L-55) PA 29.2(VI SU) Ca Penis	Clinical Posting			Micro (L-27) MI 3.3 (VI-IM, HI- PH & PA) Enteric fever	Lunch	Pharm (SGT-79,80) PH4.2 Demonstrate the effects of drugs on blood pressure (vasopressor)
2/25/2025	Tue	Pharm (L-51) PH1.44 Describe the first line antitubercular drugs, their mechanisms of action, side effects and doses.	Clinical Posting			F.M.T SGT-5 FM2.11 Autopsy procedure, Legal requirements & Chemical Analysis	Lunch	Micro SGT 81 & 82: MI8.5 ((VI-IM, CM) Health care infections -II
2/26/2025	Wed	Micro (L-28) MI 3.5 (VI-IM, HI- PH) Food Poisoning	Clinical Posting			Pharm (L-52) PH1.46 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antileprotic drugs	Lunch	Path (SGT-79,80)PA 18.2.1 C-2 CML & CLL
2/27/2025	Thu	Path (L-56) PA 29.3, 29.4, 29.5(VI SU) BPH, Ca Prostate, Prostatitis	Clinical Posting			O & G (Assessment/Feedback)	Lunch	Path (SGT-81,82)PA 19.3 Gross & M/E: Tb LN
2/28/2025	Fri	Surgery(L-19) SU 29.1- Haematuria-causes, investigations & Mgt.	Clinical Posting			Med (L- 20) IM 14.1, 14.2, 14.3: Obesity- Causes, Risk factors, monogenic forms.	Lunch	Pharm (SGT-81,82) PH4.2 Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate
3/1/2025	Sat	F.M.T L :Revision/Feedback	Module 2.4: Working in a health care team (Pathology deptt)	Module 2.4: Working in a health care team (Pathology deptt)	Pharm L: Revision/Feedback	Path L: Revision/Feedback	Lunch	Micro SGT : Revision/Feedback
3/3/2025	Mon	Path (L-57) PA 30.1(VI OG) Ca Cervix	Clinical Posting			Micro (L-29) MI 3.6 (VI-IM, HI- PH & PA) Acid peptic disease	Lunch	Pharm (SGT-81,82) PH5.1 Communicate with the patient with empathy and ethics on all
3/4/2025	Tue	Pharm (L-53) PH1.47 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in malaria, KALA-AZAR, amebiasis and intestinal helminthiasis	Clinical Posting			F.M.T SGT - 6 : FM2.21: Different types of hanging and strangulation MLI, Cause of Death	Lunch	Micro SGT 83 &84:MI 8.6 (HI-CM) Infection Control-I
3/5/2025	Wed	Micro (L-30) MI 3.7, 3.8 (VI-IM,HI-PA) Viral hepatitis - I	Clinical Posting			Pharm (L-54) PH1.47 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in malaria, KALA-AZAR, amebiasis and intestinal helminthiasis	Lunch	Path (SGT-83,84)PA 19.5 Gross & M/E: HL
3/6/2025	Thu	Path (L-58) PA 30.5(VI OG) GTN	Clinical Posting			Pharm (SDL-1) PH1.34 Acid-peptic disease and GERD	Lunch	Path (SGT-85,86)PA 19.6,19.7 Splenomegaly & Gross & M/E Specimen
3/7/2025	Fri	Surgery (L-20) SU 29.5: Renal Calculi Clinical features, Investigations and types and management.	Clinical Posting			Med (L) Assessment/Feedback	Lunch	Pharm (SGT-83,84)PH5.1 Communicate with the patient with empathy and ethics on all aspects of drug use

3/8/2025	Sat	F.M.T L 4: FM 1.10,1.11 cause of death, ICD ,death certificate	Module 2.4: Working in a health care team (Pathology deptt)	Module 2.4: Working in a health care team (Pathology deptt)	Pharm (L-55) PH1.49 Describe mechanism of action, classes, side effects, indications and contraindications of anticancer drugs	Path (L-59)PA 24.1 (VI DE) Oral Cancer	Lunch	Micro SGT 85 & 86:MI 8.6 (HI-CM) Infection Control-II
3/9/2025	SUNDAY							
3/10/2025	Mon	Path (L-60)PA 24.2 (VI IM) Peptic ulcer	Clinical Posting			Micro (L-31) MI 3.7, 3.8 (VI-IM,HI-PA) Viral hepatitis - II	Lunch	Pharm (SGT-85,86) PH5.2 Communicate with the patient regarding optimal use of a) drug
3/11/2025	Tue	Pharm (L-56) PH1.50 Describe mechanisms of action, types, doses, side effects, indications and contraindications of immunomodulators and management of organ transplant rejection	Clinical Posting			F.M.T (SGT)F.M.T SGT-7 FM2.24,2.25,2.26 (VI-SU) PM finding of different mode of thermal death & starvation	Lunch	Micro SGT 87 & 88: MI 8.7 (VI-SU, HI-CM); Infection control practice and PPE-I
3/12/2025	Wed	Micro (L-33) MI 4.2 (VI-OR) Bone and Joint infection	Clinical Posting			Pharm (L-57) PH1.51 Describe occupational and environmental pesticides, food adulterants, pollutants and insect repellents	Lunch	Path (SGT-87,88)PA 20.1 Plasma cell myeloma (DOAP)
3/13/2025	Thu	Path (L-61)PA 24.4(VI SU) Ca Stomach	Clinical Posting			Pharm (SGT-85.1,86.1) PH5.2 Communicate with the patient regarding optimal use of a) drug	Lunch	Path (SGT-89,90)PA 16.7 Cross Match-Need, Technique
3/14/2025	Fri	GH- Holi						
3/15/2025	Sat	F.M.T L -5: FM2.1,2.2,2.3,2.4 (VI-PA) Death types & Sudden & organ transplantation	Module 2.4: Working in a health care team (Pathology deptt)	Com. Med (FAP-7)Maintain communication & follow up of remedial measures (3 hours) 2			Lunch	Micro SGT-89 & 90: MI 8.7 (VI-SU,HI-CM); Infection control practice and PPE-II
3/16/2025	SUNDAY							
3/17/2025	Mon	Path (L-62)PA 24.5 (VI SU) Tb Intestine	Clinical Posting			Micro (L-34) MI 4.3 (VI-DR, SU) Skin & soft infection	Lunch	Pharm (SGT-87,88) PH5.2 Communicate with the patient regarding optimal use of a) drug
3/18/2025	Tue	Pharm (L-58) PH1.52 Describe management of common poisoning, insecticides, common sting and bites	Clinical Posting			F.M.T SGT-8 : FM2.29: Courts evidence, oath, examination in chief, cross examination, re-examination and court questions, recording of evidence,	Lunch	Micro SGT-91 & 92: MI 8.8; Food, Air and water Microbiology-I
3/19/2025	Wed	Micro (L-2) MI1.3 (HI-CM)Infectious disease	Clinical Posting			Pharm (L-59) PH1.53 Describe heavy metal poisoning and chelating agents	Lunch	Path (SGT-91,92)PA 22.1, 22.2 (VI OG) Blood Group (ABO RH) & Compatibility testing
3/20/2025	Thu	Path (L-63)PA 24.6(VI SU) IBD	Clinical Posting			(SGT-89.1,90.1) PH5.3 Motivate patients with chronic diseases to adhere to the prescribed	Lunch	Path (SGT-93,94)PA 22.4,22.5(VI SU,IM) Blood Component, Blood transfusion related infections
3/21/2025	Fri	Micro SDL-1: MI 1.5 (VI-SU) Sterilization	Clinical Posting			Path (SDL- 1) PA 4.2 Seminar - Inflammation	Lunch	Pharm (SGT-89,90) PH5.3 Motivate patients with chronic diseases to adhere

3/22/2025	Sat	F.M.T SDL-2: FM2.1,2.2,2.3,2.4 (VI-PA) Death types & Sudden & organ transplantation	PN 2.5 Therapeutic strategies including new drug development (Pharma deptt)	PN 2.5 Therapeutic strategies including new drug development (Pharma deptt)	Pharm (L-60) PH1.54 Describe vaccines and their uses	Path (L-64)PA 24.7(VI SU) Ca Colon	Lunch	Micro SGT-93 & 94: MI 8.8; Food, Air and water Microbiology-II
3/23/2025	SUNDAY							
3/24/2025	Mon	Path (L-65)PA 25.1,25.2 (VI BI, IM VI IM, SU) Hepatic Failure,Jaundice	Clinical Posting			Micro (L-24) MI 2.7 (VI-IM,HI- PA) HIV - I	Lunch	Pharm (SGT-91,92) PH5.3 Motivate patients with chronic diseases to adhere to the prescribed
3/25/2025	Tue	Pharm (L-61) PH1.55 Describe and discuss the following National Health Programmes including Immunisation, Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala Azar, Diarrhoeal diseases, Anaemia & nutritional disorders, Blindness, Non-communicable diseases, cancer and Iodine deficiency	Clinical Posting			F.M.T SGT- 9: FM3.2 identifications from Hair, Fibers, Teeth, identification from anthropometry, dactylography, poroscopy, Foot Prints, Scar, tattoos, superimposition	Lunch	Micro SGT-95 & 96: MI 8.9,10,8.11; Sample Collection-1
3/26/2025	Wed	Micro (L-25) MI 2.7 (VI-IM,HI- PA) HIV - II	Clinical Posting			Pharm (L-62) PH1.55 Describe and discuss the following National Health Programmes including Immunisation, Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala Azar, Diarrhoeal diseases, Anaemia & nutritional disorders, Blindness, Non-communicable diseases, cancer and Iodine deficiency	Lunch	Path (SGT-95,96)PA 22.6,22.7(HI MI)(VI IM) Transfusion reactions, its investigation & autologous transfusion
3/27/2025	Thu	Path (L-66) PA 25.3(VI IM) Hepatitis	Clinical Posting			Pharm (SGT-93.1,94.1) PH5.4 Explain to the patient the relationship between cost of treatment	Lunch	Path (SGT-97,98)PA 26.4, 26.5(HI MI) (VI IM,CM) Tb, Occupational Lung Ds
3/28/2025	Fri	Micro SDL-2: MI 1.5 (VI-SU) Disinfection	Clinical Posting			Path (SDL-2)- PA 6 Seminar Neoplasia	Lunch	Pharm (SGT-93,94) PH5.4 Explain to the patient the relationship between cost of

3/29/2025	Sat	F.M.T L -6: FM 2.5,2.6,2.7 (VI-PS, PA) Moment, Mode, presumption of Death, suspended animation	PN 2.5 Therapeutic strategies including new drug development (Pharma deptt)	PN 2.5 Therapeutic strategies including new drug development (Pharma deptt)	Pharm (L-63) PH1.55 Describe and discuss the following National Health Programmes including Immunisation, Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala Azar, Diarrhoeal diseases, Anaemia & nutritional disorders, Blindness, Non-communicable diseases, cancer and Iodine deficiency	Path (L-67) PA 25.4 (VI IM, SU) ALD & Cirrhosis	Lunch	Micro SGT-97 & 98: MI 8.9,10,8.11; Sample Collection-2	
3/30/2025	SUNDAY								
3/31/2025	Mon	Path (L-68) PA 25.5 (VI IM, SU) Portal HTN	Clinical Posting			Micro (L-42) MI 8.3 (VI-IM & HI-PA) Oncogenic viruses	Lunch	Pharm (SGT-)	Pharma (SGT) revision
4/1/2025	Tue	Pharm (L-64) PH1.55 Describe and discuss the following National Health Programmes including Immunisation, Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala Azar, Diarrhoeal diseases, Anaemia & nutritional disorders, Blindness, Non-communicable diseases, cancer and Iodine deficiency	Clinical Posting			F.M.T SGT-10 FM3.6,3.7,3. (VI-SU): healing of injury and fracture of bones with its medico-legal importance, examination and certification of wounds, discuss different type of weaponsF.M.T (SGT)F.M.T SGT-19 & 20: FM3.2 identifications from Hair, Fibers, Teeth, identification from anthropometry, dactylography, poroscopy, Foot Prints, Scar, tattoos, superimposition	Lunch	Micro SGT-99 & 100: MI 8.12; Lab Practices-I	
4/2/2025	Wed	Micro (L-43) MI 8.1(VI-IM) Zoonotic Diseases	Clinical Posting			Pharm (L-65) PH1.56 Describe basic aspects of Geriatric and Pediatric pharmacology	Lunch	Path (SGT-99,100)PA 26.4, 26.5(HI MI) Gross & M/s - TB Lung, Occupational Lung Ds	
4/3/2025	Thu	Term II							
4/4/2025	Fri	Term II							
4/5/2025	Sat	Term II							
4/6/2025	SUNDAY	GH- Ram Navmi							
4/7/2025	Mon	Term II							
4/8/2025	Tue	Term II							
4/9/2025	Wed	Term II							
4/10/2025	Thu	Term II							
4/11/2025	Fri	Term II							
4/12/2025	Sat	F.M.T L-7: FM 2.15, 2.16,2.17 custodial death, bundle of bones exhumation	PN 2.5 Therapeutic strategies including new drug development (Pharma deptt)	PN 2.5 Therapeutic strategies including new drug development (Pharma deptt)	Pharm (L-66) PH1.57 Describe drugs used in skin disorders	Path (L-69) PA 33.1(VI AN, OR) (HI MI) Osteomyelitis	Lunch	Micro SGT-101 & 102: MI 8.12; Lab practices-II	

4/13/2025	SUNDAY					
4/14/2025	Mon	Path (L-70) PA 33.2, 33.4 (VI OR) Bone tumour - Pathogenesis, Classifications, Pagets Ds Osteochondroma, Osteosarcoma, Chondrosarcoma, Ewings Tumor	Clinical Posting	Micro (L-44) MI 8.2 (VI-IM & HI-PA) Opportunistic infections	Lunch	Pharm (SGT-95,96) PH5.5 Demonstrate an understanding of the caution in prescribing drugs likely to produce dependence and recommend the line of management
4/15/2025	Tue	Pharm (L-67) PH1.58 Describe drugs used in Ocular disorders	Clinical Posting	F.M.T SGT 11: FM3.14, 3.13, 3.14, 3.15 (VI-OG): Sexual Offences-IF.M.T (SGT) F.M.T SGT-11 FM3.2 identifications from Hair, Fibers, F.M.T SGT-21 & 22: FM3.6,3.7,3. (VI-SU): healing of injury and fracture of bones with its medico-legal importance, examination and certification of wounds, discuss different type of weapons	Lunch	Micro SGT-103 & 104: MI 8.13; Choosing Diagnostic methods
4/16/2025	Wed	Micro (L-45) MI 8.4 (VI-IM, CM) Emerging Infections	Clinical Posting	Pharm (L-68) PH1.58 Describe drugs used in Ocular disorders	Lunch	Path (SGT-101,102) PA 26.6, 26.7 (VI IM, CM) Tumour of Lung, Pluera, Mesothelioma
4/17/2025	Thu	Path (L-71) PA 33.3 (VI OR) Soft tissue tumors	Clinical Posting	Pharm (SDL- PH1.58 Describe drugs used in Ocular disorders)	Lunch	Path (SGT-103,104) PA 26.1, 26.2 Gross & M/s - Pneumonia, Lung abcess
4/18/2025	Fri	GH- Good Friday				
4/19/2025	Sat	F.M.T L-8: FM2.18, 2.19 (VI-SU, AN) Crime Scene Investigation, operative death	PN 2.1 Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (Microbiology deptt)	Com. Med(FAP-8) Maintain communication & follow up of remedial measures (3 hours) 3	Lunch	Micro SGT-105 & 106: MI 8.14 (VI-AETCOM) Lab Practices
4/20/2025	SUNDAY					
4/21/2025	Mon	Path (L-72) PA 33.5 (VI OR) Rheumatoid Arthritis	Clinical Posting	Micro (L-48) MI 8.8 Food, Air and water Microbiology	Lunch	Pharm (SGT-97,98) PH5.5 Demonstrate an understanding of the caution in
4/22/2025	Tue	Pharm (L-69) PH3.3 Perform a critical evaluation of the drug promotional literature	Clinical Posting	F.M.T SGT-12 FM 3.24, 3.25, 3.26, 3.27, 3.28 Surgical Methods of Contraception, National Health Survey, ART Clinics, Abortion Methods F.M.T (SGT)	Lunch	Micro SGT-107 & 108: MI 8.15; Interpretation of Results-I
4/23/2025	Wed	Micro (L-46) MI 8.5 (VI-IM, CM) Health care infections	Clinical Posting	Pharm (L-70) PH1.59 Describe and discuss the following: Essential medicines, Fixed dose combinations, Over the counter drugs, Herbal medicines	Lunch	Path (SGT-105,106) PA 26.6, 26.7 Gross - Lung Ca, M/s - SCC Lung

4/24/2025	Thu	Path (L-73) PA 31.1, 31.4-(VI SU, AN) Benign Breast ds, Gynaecomastia	Clinical Posting			Pharm (SDL-PH5.6 Demonstrate ability to educate public & patients about various)	Lunch	Path (SGT-107,108)PA 35.1,35.3 (HI MI) (VI IM) CSF Parameters & finding - Meningitis,Urine analysis,Semen Analysis
4/25/2025	Fri	Micro SDL-3: MI 1.6 (HI-PH) Drug resistance & ABST-I	Clinical Posting			Path (SDL- 3) PA 6.3 6.7 Poster presentation- Shock, Infarct	Lunch	Pharm (SGT-99,100) PH5.6 Demonstrate ability to educate public & patients about various
4/26/2025	Sat	F.M.T SDL -3 F.M.T SGT-17 &18: FM2.31- 2.35 (VI-AETCOM, CM, IM): Conduction of Medicolegal Autopsy in cause of death in various situations-II	PN 2.1 Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (Microbiology deptt)	PN 2.1 Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (Microbiology deptt)	Pharm (L-71)PH1.59 Describe and discuss the following: Essential medicines, Fixed dose combinations, Over the counter drugs, Herbal medicines	Path (L-74) PA 31.2,31.3(VI SU) Ca Breast	Lunch	Micro SGT-109 & 110: MI 8.15; Interpretation of results- II
4/27/2025	SUNDAY							
4/28/2025	Mon	Path (L-75) PA 34.1,34.2,34.3(VI DR) SCC skin, BCC skin, Melonoma	Clinical Posting			Micro (L-47) MI 8.6 (HI-CM) Infection Control	Lunch	Pharm (SGT-101,102) PH5.6 Demonstrate ability to educate public & patients about various
4/29/2025	Tue	Pharm (L-72) PH1.60 Describe and discuss Pharmacogenomics and Pharmacoeconomics	Clinical Posting			F.M.T (SGT)SGT- 13 FM 3.29, 3.30, 3.31,3.32, 3.33: Child Abuse, Torture & Injuries, Human Rights, Professionalism in Medicolegal situations	Lunch	Micro SGT -111 & 112 MI 2.5 (VI-IM & HI-PA) Diagnostic methods of microbial agents causing Kala Azar & Filaria- Revision
4/30/2025	Wed	Micro (L-52) MI8.16 (HI-CM) National Health Program	Clinical Posting			Pharm (L-73) PH1.60 Describe and discuss Pharmacogenomics and Pharmacoeconomics	Lunch	Path (SGT-109,110)PA 23.3 C-1 Thyroid Fuction Test,KFT,LFT
5/1/2025	Thu	Path (L-76)PA 34.4 (VI DR) Common Tumors of Skin	Clinical Posting			Pharm (SDL- Describe and discuss Pharmacogenomics)	Lunch	Path (SGT-111,112)PA 28.1, 28.7(VI IM) Kidney Histo, Glomerular finding in SLE,
5/2/2025	Fri	Micro SDL-4: MI 1.6 (HI-PH) Drug resistance & ABST-II	Clinical Posting			Path (SDL- 4) PA 13.5 Periperal smear staining- Perform/Identify/Describe	Lunch	Pharm (SGT-103,104) PH5.7 Demonstrate an understanding of the legal and ethical aspects of
5/3/2025	Sat	F.M.T L-9: FM 2.20 Mechanical asphyxia: Classification MLI	PN 2.1 Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (Microbiology deptt)	PN 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters (Microbiology deptt)	Pharm (L-74) PH1.61 Describe and discuss dietary supplements and nutraceuticals	Path (L-77) PA 36.1 (VI OP) Retinoblastoma	Lunch	Micro SGT 113 &114: MI 2.7 (VI-IM, HI-PA) Diagnostic methods in HIV-Revision
5/4/2025	SUNDAY							
5/5/2025	Mon	Path (L-78) PA 32.1,32.2,(VI AN, PY, IM, SU) Thyroid disorder 1	Clinical Posting			Micro (L-53) MI1.4, 1.5 (VI-SU) Sterilization & Disinfection- Revision	Lunch	Pharm (SGT-105,106) FM8.7 Describe simple Bedside clinic tests to detect poison/drug in a
5/6/2025	Tue	Pharm (L-75) PH1.62 Describe and discuss antiseptics and disinfectants	Clinical Posting			F.M.T (SGT) 14: FM2.30, 2.31: Medico-legal practice, medico- legal autopsies, alleged negligence, dowry death, death in custody, human rights, exhumation.	Lunch	Micro SGT 115 &116: MI 3.1, 3.2 (VI-IM & PE, HI-PA) Diagnostic methods in Diarrhea & Dysentery Revision

5/7/2025	Wed	Micro (L-54) MI1.6 (HI-PH) Drug resistance & ABST-Revision	Clinical Posting			Pharm (L-76) PH1.63 Describe Drug Regulations, acts and other legal aspects	Lunch	Path (SGT-113,114)PA 28 Gross & M/s of Kidney
5/8/2025	Thu	Path (L-79) PA 32.3,32.5(VI,PY,IM) Hyperparathyroidism,,Hypertoxic osis	Clinical Posting			Pharm (SDL- Describe Drug Regulations, acts and other legal aspects)	Lunch	Path (SGT-115,116)PA 28.10, 28.11(VI SU, AN) Pyelonephritis, Vascular ds of Kidney
5/9/2025	Fri	Micro SDL- 5: MI1.10 (VI-PE) Antigen antibody reaction, Hypersensitivi ty, Immunodefici ency disease-I	Clinical Posting			Path (SDL-5) - Blood Group & Cross Match	Lunch	Pharm (SGT-107,108) FM8.7 Describe simple Bedside clinic tests to detect poison/drug in a patient's body fluids
5/10/2025	Sat	F.M.T SDI-4: FM3.1(VI-AN): Ossification centres, MLI of age	PN 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters (Microbiology deptt)	PN 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters (Microbiology deptt)	Pharm (L-76.1) PH1.63 Describe Drug Regulations, acts and other legal aspects	Path (L-80) PA 32.6(VI SU) Pancreatic Ca	Lunch	Micro SGT 117 &118: MI1.10 (VI-PE) Antigen antibody reaction, Hypersensitivity, Immunodeficiency disease- Revision
5/11/2025	SUNDAY							
5/12/2025	Mon	Path Revision PA 5.1 (VI SU) Wound repair & Healing, Regeneration	Clinical Posting			Micro (L-55) MI 1.7 (HI-PA) Immunological mechanisms- Revision	Lunch	Pharm (SGT-109,110) FM8.8 Describe basic methodologies in treatment of poisoning:
5/13/2025	Tue	Pharm (L-77) PH1.64 Describe overview of drug development, Phases of clinical trials and Good Clinical Practice	Clinical Posting			F.M.T (SGT)15 FM2.31- 2.35 Conduction of Medicolegal Autopsy in cause of death in various situations-I	Lunch	Micro SGT-119 & 120: MI 1.4, 1.5 (VI-SU) Sterilization & Disinfection-Revision
5/14/2025	Wed	Micro (L-56) MI1.8 (VI-PE & HI-PA) Immune response-Revision	Clinical Posting			Pharm (L-78) PH1.64 Describe overview of drug development, Phases of clinical trials and Good Clinical Practice	Lunch	Path (SGT-117,118)PA 28.14, 28.16 (VI PE, SU) Renal tumours, urothelial tumours
5/15/2025	Thu	Path Revision PA 6.1 (VI IM) Edema	Clinical Posting			Pharm (SDL-Describe overview of drug development, Phases of clinical trials)	Lunch	Path (SGT-119,120)PA 29 Gross & M/s of BPH, Ca Prostate, Testicular tumors
5/16/2025	Fri	Micro SDL-6: MI1.10 (VI-PE) Antigen antibody reaction, Hypersensitivity, Immunodeficien cy disease-II	Clinical Posting			Path Revision PA 6.5,6.6 Embolism, Ishemia & Infarction	Lunch	Pharm (SGT-111,112) FM8.8 Describe basic methodologies in treatment of poisoning: decontamination, supportive therapy, antidote therapy, procedures
5/17/2025	Sat	F.M.T L-10: FM2.22, 2.23 traumatic asphyxia & drowning	PN 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters (Microbiology deptt)	Com. Med(FAP-9)Take part in environment protection and sustenance activities. (3 Hours) 1			Lunch	Micro SGT 121 & 122: MI 8.14 (VI-AETCOM) Lab Practices- Revision
5/18/2025	SUNDAY							
5/19/2025	Mon	Path Revision PA 7.3,7.4 Paraneoplastic syndromes.Carcinogenesis	Clinical Posting			Micro (L-57) MI1.9 (VI-PE) Vaccines-Revision	Lunch	Pharm (SGT-113,114) FM9.1 Describe General Principles and basic methodologies in treatment

5/20/2025	Tue	Pharm (L-79) PH1.27 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugs and drugs used in shock	Clinical Posting			F.M.T (SGT)16 FM 2.35 (VI-AETCOM): Professionalism while Conducting a Medicolegal Autopsy	Lunch	Micro SGT 123 & 124 MI 8.13; Choosing Diagnostic methods- Revision
5/21/2025	Wed	Micro (L-58) MI1.10 (VI-PE) Antigen antibody reaction, Hypersensitivity, Immunodeficiency disease- Revision	Clinical Posting			Pharm (L-80) PH1.36 Thyroid & Antithyroid Revision	Lunch	Path (SGT-121,122)PA 30.2, 30.3 (VI OG) Ca Endometrium, Leiomyoma, LMS
5/22/2025	Thu	Path Revision PA 16.4 (VI IM, BI)Acquired Hemolytic anemias	Clinical Posting			Pharm (SDL-Thyroid & Antithyroid Revision)	Lunch	Path (SGT-123,124)PA 30.4(VI OG) Ovarian Tumours
5/23/2025	Fri	Micro SDL 7: MI 2.5 (VI-IM & HI-PA) Kala Azar, Filariasis-I	Clinical Posting			Path (SDL- 6) Revision- CBC Interpretation	Lunch	Pharm (SGT-115,116) FM9.1 Describe General Principles and basic
5/24/2025	Sat	F.M.T SDL -5 FM1.9 (VI- RD,SU, IM, PE) : Documentation, case records, accident register, wound , drunkenness , fitness certificate	PN 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters (Microbiology deptt)	PN 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters (Microbiology deptt)	Pharm (L-)	Path Revision PA 18.2 C-2 Chronic leukemia	Lunch	Micro SGT 125 &126: MI 1.6 (HI- PH) Drug resistance & ABST-I- Revision
5/25/2025	SUNDAY							
5/26/2025	Mon	Path Revision PA 19.1,19.2 (VI SU) Lymphadenopathy, TB LN	Clinical Posting			Micro (L-59) MI 2.1 (VI-IM & HI-PA) Rheumatic fever- Revision	Lunch	Pharm (SGT-117,118) FM9.2 Describe General Principles and basic methodologies in treatment
5/27/2025	Tue	Pharm (L-81) PH1.15 Part-1 Skeletal Muscle Relaxants Revision	Clinical Posting			F.M.T (SGT) 17: FM3.1(VI-AN): Ossification centres, MLI of age	Lunch	Micro SGT-127 & 128: MI 1.2 Staining methods, Stool Examination- Revision
5/28/2025	Wed	Micro (L-60) MI 2.2 (VI-IM & HI-PA) Infective endocarditis - Revision	Clinical Posting			Pharm (L-82) PH1.17 Local Anesthetics Revision	Lunch	Path (SGT-125,126)PA 30.6-30.9 (VI OG) Cervicitis, Endometriosis, Adenomyosis, Endometrial hyperplasia
5/29/2025	Thu	Path Revision PA 21.1 Hemostasis	Clinical Posting			Pharm (SDL- Local Anesthetics)	Lunch	Path (SGT-127,128)PA 30 Gross & M/s of FGT
5/30/2025	Fri	Micro SDL 8: MI 2.5 (VI-IM & HI-PA) Kala Azar, Filariasis-II	Clinical Posting			Path (SDL- 7) Revision- TFT,KFT,LFT	Lunch	Pharm (SGT-119,120) FM9.2 Describe General Principles and basic
5/31/2025	Sat	F.M.T L-11: FM2.24, 2.25 (VI-PE) Thermal Death , Their causes, MLI of various mode of thermal death.	PN 2.2 Emerging and Re-emerging infections, early identification and control of new infections (Community Medicine deptt)	PN 2.2 Emerging and Re-emerging infections, early identification and control of new infections (Community Medicine deptt)	Pharm (L-83) PH1.18 Part-1 General aneshthetics Revision	Path Revision PA 21.2(VI PE) Vascular and platelets disorder- ITP, Hemophillia	Lunch	Micro SGT-129 & 130: MI 1.4, 1.5 (VI-SU) Sterilization & Disinfection- Revision
6/1/2025	SUNDAY							
6/2/2025	Mon	Path Revision PA 35.2 (VI PE) CNS tumours	Clinical Posting			Micro (L-61) MI 2.4 (VI-IM & HI-PA) Anemia - Revision	Lunch	Pharm (SGT-121,122) FM9.2 Describe General Principles and basic methodologies in treatment
6/3/2025	Tue	Pharm (L-84) PH1.20 Alcohols Revision	Clinical Posting			F.M.T (SGT)- Feedback/ Assessment	Lunch	Micro SGT- 131 & 132: MI 1.6 (HI- PH) Drug resistance & ABST- Revision
6/4/2025	Wed	Micro (L-62) I 2.5 (VI-IM & HI- PA) Kala Azar, Filariasis-Revision	Clinical Posting			Pharm (L-85) PH1.22 Drug Deaddiction Revision	Lunch	Path (SGT-129,130)PA 24.3,24.4 Gross & M/E - Peptic ulcer, Ca Stomach

6/5/2025	Thu	Path Revision PA 28.6,28.7(VI IM) IgA Nephropathy, glomerular manifestations of systemic disease	Clinical Posting			Pharm (SDL- Drug uses in viral disease (non-retroviral))	Lunch	Path (SGT-131,132)PA 24.5 24.6,24.7 Gross& M/E - IBD, TB intestine,Ca Colon
6/6/2025	Fri	GH- Id-UI-Adha						
6/7/2025	Sat	F.M.T L-12: FM2.27, 2.28 (VI-AN, PE): infanticide different signs of IUD, Live birth, age determination, type of syndrome Related to IUD	PN 2.2 Emerging and Re-emerging infections, early identification and control of new infections (Community Medicine deptt)	PN 2.2 Emerging and Re-emerging infections, early identification and control of new infections (Community Medicine deptt)	Pharm (L-86) PH.123 Drug deaddiction Revision	Path Revision PA 28.8, 28.9(VI IM) ATN	Lunch	Micro SGT-133 & 134: MI 2.1 (VI-IM & HI-PA) Diagnostic methods in Rheumatic fever- Revision
6/8/2025		SUNDAY						
6/9/2025	Mon	Summer Vacations						
6/10/2025	Tue	Summer Vacations						
6/11/2025	Wed	Summer Vacations						
6/12/2025	Thu	Summer Vacations						
6/13/2025	Fri	Summer Vacations						
6/14/2025	Sat	Summer Vacations						
6/15/2025		SUNDAY						
6/16/2025	Mon	Path Revision PA 29.1(VI SU) Testicular tumours	Clinical Posting			Micro (L-63) MI 2.6 (VI-IM) Hookworm, Roundworm - Revision	Lunch	Pharm (SGT-123,124) PH1.14 Part-1 Cholinergic Drugs -1
6/17/2025	Tue	Pharm (L-87) PH1.24 Druretics Revision	Clinical Posting			F.M.T (SGT) 18: FM3.3 Mechanical injuries and wounds: Define, Classification , and injuries Medicolegal aspect (L)	Lunch	Micro SGT-135 & 136: MI 2.3 (VI-IM & HI-PA) Diagnostic methods in Endocarditis- Revision
6/18/2025	Wed	Micro (L-64) MI 2.7 (VI-IM,HI-PA) HIV-Revision	Clinical Posting			Pharm (L-88) PH1.26 Part 1 Ras,ACE Inhibitors & ATI Blockers Revision	Lunch	Path (SGT-133,134)PA 25.3 Gross - Fatty Liver, M/s Fatty liver, Hepatitis
6/19/2025	Thu	Path Revision PA 29.2(VI SU) Ca Penis	Clinical Posting			Pharm (SDL- PH1.26 Part 1 Ras,ACE Inhibitors & ATI Blockers Revision)	Lunch	Path (SGT-135,136)PA 25.6 LFT, Viral Serology Panel, Obstructive vs Non obstructive jaundice
6/20/2025	Fri	Micro SDL-9: MI 8.13 Choosing Diagnostic methods.	Clinical Posting			Path (SDL- 8) Revision- OSPE	Lunch	Pharm (SGT-125,126) PH1.14 Part-1 Cholinergic Drugs -1
6/21/2025	Sat	F.M.T SDL 6 - FM2.31- 2.35 (VI-AETCOM, CM, IM): Conduction of Medicolegal Autopsy in cause of death in various situations-II	PN 2.2 Emerging and Re-emerging infections, early identification and control of new infections (Community Medicine deptt)	Com. Med(FAP-10)Take part in environment protection and sustenance activities. (3 Hours) 2			Lunch	Micro SGT-137 & 138: MI 2.4 (VI-IM & HI-PA) Diagnostic methods of microbial agents causing anemia- Revision
6/22/2025		SUNDAY						
6/23/2025	Mon	Path Revision PA 30.1(VI OG) Ca Cervix	Clinical Posting			Micro (L-65) MI 3.5 (VI-IM, HI- PH) Food Poisoning- Revision	Lunch	Pharm (SGT-127,128) Revision class

6/24/2025	Tue	Pharm (L-89) PH1.24 Diuretics Revision	Clinical Posting			F.M.T (SGT)19 FM3.4, 3.5 (VI-SU): Define injuries, assault, hurt, grievous and dangerous injuries antemortem and post mortem injuries	Lunch	Micro SGT-139 & 140: MI 2.5 (VI-IM & HI-PA) Diagnostic methods of microbial agents causing Kala Azar & Filaria- Revision
6/25/2025	Wed	Micro (L-66) MI 3.1, 3.2 (VI-IM & PE, HI-PA) Diarrhea & Dysentery- Revision	Clinical Posting			Pharm (L-90) PH1.24 Part 3 Anti-diuretics Hormones (ADH) Revision	Lunch	Path (SGT-137,138) PA 31.3 (VI SU) Gross- Fibroadenoma, Ca Breast, M/E- Fibroadenoma, Ca Breast
6/26/2025	Thu	Path Revision PA 24.6(VI SU) IBD	Clinical Posting			Pharm (SDL- Anti-diuretics Hormones)	Lunch	Path (SGT-139,140)PA 32.4(VI PY, IM) DM
6/27/2025	Fri	Micro SDL-10 MI 3.7, 3.8 (VI-IM,HI-PA) Viral hepatitis	Clinical Posting			Path (SDL- 9) Revision- Lab Instrument - 1	Lunch	Pharm (SGT-131,132) PH1.14 Cholinergic drugs part-1
6/28/2025	Sat	F.M.T SDL 7 Surgical Methods of Contraception, National Health Survey, ART Clinics, Abortion Methods	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	Pharm (L-91) PH1.26 Part 1 RAS, ACE inhibitors & ATI Blockers-I	Path Revision PA 24.7(VI SU) Ca Colon	Lunch	Micro SGT-141 & 142: MI 2.6 (VI-IM) Hookworm, Roundworm - Revision
6/29/2025		SUNDAY						
6/30/2025	Mon	Preparatory Leave						
7/1/2025	Tue	Pre-University Exams						
7/2/2025	Wed	Pre-University Exams						
7/3/2025	Thu	Pre-University Exams						
7/4/2025	Fri	Pre-University Exams						
7/5/2025	Sat	Pre-University Exams						
7/6/2025		SUNDAY						
7/7/2025	Mon	Pre-University Exams						
7/8/2025	Tue	Pre-University Exams						
7/9/2025	Wed	Pre-University Exams						
7/10/2025	Thu	Pre-University Exams						
7/11/2025	Fri	Pre-University Exams						
7/12/2025	Sat	Pre-University Exams						
7/13/2025		SUNDAY						
7/14/2025	Mon	Pre-University Exams						
7/15/2025	Tue	Pre-University Exams						
7/16/2025	Wed	Pre-University Exams						
7/17/2025	Thu	Pre-University Exams						
7/18/2025	Fri	Pre-University Exams						
7/19/2025	Sat	Pre-University Exams						
7/20/2025		SUNDAY						
7/21/2025	Mon	Path Revision PA 25.3(VI IM) Hepatitis	Clinical Posting			Micro (L-67) MI 3.3 (VI-IM, HI- PH & PA) Enteric fever- Revision	Lunch	Pharm (SGT-133,134) PH1.19 part-1 Neurotransmission In CNS Revision
7/22/2025	Tue	Pharm (L-92) PH1.27 Part-1 Antihypertensive drugs Revision	Clinical Posting			F.M.T (SGT) 20 FM3.9, 3.10 (VI-SU,OR): Fire arm injuries types , mechanism , caliber, range, choking, blast injuries	Lunch	Micro SGT-143 & 144; MI 2.7 (VI-IM, HI-PA) Diagnostic methods in HIV- Revision
7/23/2025	Wed	Micro (L-68) MI 3.7, 3.8 (VI-IM,HI-PA) Viral hepatitis - Revision	Clinical Posting			Pharm (L-93) PH1.34 Part-3 Treatment of shock-Revision	Lunch	Path (SGT-141,142)PA 32.7, 32.8, 32.9(VI PI, IM, AN,SU) Adrenal insufficiency, Cushing, Adrenal Neoplasm

7/24/2025	Thu	Path Revision PA 25.4 (VI IM, SU) ALD & Cirrhosis	Clinical Posting			Pharm (SDL-Treatment of shock)	Lunch	Path (SGT-143,144)PA 33.2,33.3,33.4 Gross & M/s of bone tumours & soft
7/25/2025	Fri	Micro SDL-1: MI 1.5 (VI-SU)Sterilization	Clinical Posting			Path (SDL- 10) Revision- Lab Instrument - 2	Lunch	Pharm (SGT-135,136) PH1.2 Therapeutic Drug Monitoring Revision
7/26/2025	Sat	F.M.T SDL 8- Court procedures Dying Declaration	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	Pharm (L-92.1) PH1.27 Part- 1 Antihypertensive drugs Revision	Path Revision PA 33.2, 33.4 (VI OR)Bone tumour - Pathogenesis, Classifications, Pagets Ds Osteochondroma, Osteosarcoma, Chondrosarcoma, Ewings Tumor	Lunch	Micro SGT-145 & 146; MI 3.6 (VI-IM, HI- PH & PA) Diagnostic methods in Acid peptic disease- Revision
7/27/2025	SUNDAY							
7/28/2025	Mon	Path Revision PA 33.5(VI OR) Rheumatoid Arthritis	Clinical Posting			Micro (L-69) MI 3.6 (VI-IM, HI- PH & PA) Acid peptic disease- Revision	Lunch	Pharm (SGT-137,138) PH1.14 Cholinergic drugs part-1 Cholinergic drugs-Revision Part-2
7/29/2025	Tue	Pharm (L-94) PH1.34 Part-1 Acid- Peptic Disease and GERD- Revision	Clinical Posting			F.M.T (SGT) 21: FM3.17 (VI- OG, PS): Sexual Perversions	Lunch	Micro SGT-147 & 148: MI 3.7, 3.8 VI-IM, HI-PA) Diagnostic methods in Viral Hepatitis- Revision
7/30/2025	Wed	Micro (L-70) MI 4.2 (VI-OR) Bone and Joint infection-Revision	Clinical Posting			Pharm (L-95) PH1.34 Acid Peptic disease and GERD- Revision	Lunch	Path (SGT-145,146)PA 13.5 Revision Hb Estimation
7/31/2025	Thu	Path Revision PA 31.1, 31.4-(VI SU, AN) Benign Breast ds, Gynaecomastia	Clinical Posting			Pharm (SDL- Acid Peptic disease and GERD-Revision)	Lunch	Path (SGT-147,148)PA 13.5 Revision RBC Count, RBC indices & Reticulocyte count,WBC count & Platelet count
8/1/2025	Fri	Micro SDL-2: MI 1.5 (VI-SU) Disinfection	Clinical Posting			Path (SDL- 11) Revision- Staining Techniques	Lunch	Pharm (SGT-139,140) PH1.14 Cholinergic drugs part-1
8/2/2025	Sat	F.M.T (L)- Revision	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	Pharm (L-94.1) PH1.34 Part- 1 Acid-Peptic Disease and GERD- Revision	Path Revision PA 31.2,31.3(VI SU) Ca Breast	Lunch	Micro SGT -111 & 112 MI 2.5 (VI-IM & HI- PA) Diagnostic methods of microbial agents causing Kala Azar & Filaria- Revision
8/3/2025	SUNDAY							
8/4/2025	Mon	Path Revision PA 34.1,34.2,34.3(VI DR) SCC skin, BCC skin, Melonoma	Clinical Posting			Micro (L-71) MI 5.1 (VI- IM,PE& HI-PA) Meningitis- Revision	Lunch	Pharm (SGT-141,142) PH1.19 part-1 Neurotransmission In CNS Revision
8/5/2025	Tue	Pharm (L-96) PH1.37 Anterior Pituitary Hormones- Revision	Clinical Posting			F.M.T (SGT)-22 FM3.11, 3.12 (VI- SU, OR): Regional Injuries (L)	Lunch	Micro SGT 113 &114: MI 2.7 (VI-IM, HI- PA) Diagnostic methods in HIV-Revision
8/6/2025	Wed	Micro (L-72) MI 5. 2 (VI-IM,PE & HI-PA) Encephalitis- Revision	Clinical Posting			Pharm (L-97) PH1.29 Part-1 Drugs used in congestive heart failure Revision	Lunch	Path (SGT-149,150)PA 14.3 Revision CBC & PS interpretation of microcytic anemia
8/7/2025	Thu	Path Revision PA 34.4 (VI DR) Common Tumors of Skin	Clinical Posting			Pharm (SDL- Drugs used in congestive heart failure Revision)	Lunch	Path (SGT-151,152)PA 15.3 Revision CBC & PS interpretation of macrocytic anemia
8/8/2025	Fri	Micro SDL- 5: MI1.10 (VI-PE) Antigen antibody reaction, Hypersensitivi ty, Immunodefici ency disease-I	Clinical Posting			Path (SDL- 12) Revision- Urine examination	Lunch	Pharm (SGT-143,144) Pharm (SGT- 137,138) PH1.14 Cholinergic drugs part-1 Cholinergic drugs-Revision Part-2 Revision
8/9/2025	Sat	GH- Rakshabandhan						
8/10/2025	SUNDAY							

8/11/2025	Mon	Path Revision PA 32.3,32.5(VI,PY,IM) Hyperparathyroidism,,Hypertoxic osis	Clinical Posting			Micro (L-73) MI 1.7 (HI-PA) Immunological mechanisms- Revision	Lunch	Pharm (SGT-145,146) PH1.14 Part-1 Cholinergic Drugs -1 Revision
8/12/2025	Tue	Pharm (L-98) H1.37 Anterior Pituitary Hormones Revision	Clinical Posting			F.M.T (SGT) 23 (VI-AN): Ossification centres, MLI of age	Lunch	Micro SGT 117 &118: MI1.10 (VI-PE) Antigen antibody reaction, Hypersensitivity, Immunodeficiency
8/13/2025	Wed	Micro (L-74) MI 1.7 (HI-PA) Immunological mechanisms- Revision	Clinical Posting			Pharm (L-99) PH1.37 Androgens & Antagonists Revision	Lunch	Path (SGT-153,154)PA 16.5 Revision (VI IM) Describe PS in different Hemolytic anemias
8/14/2025	Thu	Path Revision PA 2.1,,2.2 Cell Injury	Clinical Posting			Pharm (SDL- Androgens & Antagonists Revision)	Lunch	Path (SGT-155,156)PA 16.6 Revision CBC & PS interpretation of Hemolytic anemia
8/15/2025	Fri	GH- Independence Day						
8/16/2025	Sat	GH- Janmashtami						
8/17/2025		SUNDAY						
University Exams Tentatively								
8/18/2025	Mon	Path Revision PA 2.4 Necrosis	Clinical Posting			Micro (L-75) MI 7.2 (VI-DR, OG) STD -Revision	Lunch	Pharm (SGT-147,148) FM9.2 Describe General Principles and basic
8/19/2025	Tue	Pharm (L-): Revision/Feedback	Clinical Posting			F.M.T (SGT)-	Lunch	Micro SGT-119 & 120: MI 1.4, 1.5 (VI-SU) Sterilization & Disinfection-Revision
8/20/2025	Wed	Micro (L-76) MI 7.3 (VI-IM) UTI- Revision	Clinical Posting			Pharm (L-99.1) PH1.37 Androgens & Antagonists Revision	Lunch	Path (SGT-157,158)PA 18.2.1 Revision AML & ALL
8/21/2025	Thu	Path Revision PA 2.7 Cellular aging and apoptosis	Clinical Posting			Pharm (SDL- Androgens & Antagonists Revision)	Lunch	Path (SGT-159,160)PA 18.2.1 Revision CML & CLL
8/22/2025	Fri	Micro SDL 7: MI 2.5 (VI-IM & HI-PA) Kala Azar, Filaria-I	Clinical Posting			Path (SDL- 13) Revision- PS examination	Lunch	Pharm (SGT-149,150) FM8.7 Describe simple Bedside clinic tests to detect
8/23/2025	Sat	F.M.T (L)- Revision	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	PN 2.4 Vaccination strategies including vaccine development & Implementation (Community Medicine deptt)	Pharm (L-99.2) PH1.37 Androgens & Antagonists Revision	Path Revision PA 3.1 Amylodosis	Lunch	Micro SGT 123 & 124 MI 8.13; Choosing Diagnostic methods- Revision
8/24/2025		SUNDAY						
8/25/2025	Mon	Path Revision PA 19.4 (VI SU) C-1 Hodgkin Lymphoma	Clinical Posting			Micro (L-77) MI8.2 (VI-IM & HI-PA) Opportunistic infections- Revision	Lunch	Pharm (SGT-151,152) PH1.14 Cholinergic drugs part-1 Cholinergic drugs-Revision Part-2
8/26/2025	Tue	Pharm (L-): Revision/Feedback	Clinical Posting			F.M.T (SGT)	Lunch	Micro SGT-127 & 128: MI 1.2 Staining methods, Stool Examination- Revision
8/27/2025	Wed	Micro (L-78) MI8.1(VI-IM) Zoonotic Diseases-Revision	Clinical Posting			Pharm (L-90.1) PH1.24 Part 3 Anti-diuretics Hormones (ADH) Revision	Lunch	Path (SGT-161,162)PA 19.5 Revision Gross & M/E: HL
8/28/2025	Thu	Path Revision PA 19.4(VI SU) C-2 Non Hodgkin Lymphoma,HL vs NHL	Clinical Posting			Pharm (SDL- PH1.24 Part 3 Anti-diuretics Hormones (ADH) Revision)	Lunch	Path (SGT-163,164,165)PA 19.6,19.7 Revision Splenomegaly & Gross & M/E Specimen Enlarged Spleen,TB Lung,
8/29/2025	Fri	Micro SDL-9: MI 8.13 Choosing Diagnostic methods	Clinical Posting			Path (SDL- 14) Revision- Blood Group & Cross Match	Lunch	Pharm (SGT-153,154) PH5.2 Communicate with the patient regarding optimal use of a) drug
8/30/2025	Sat	F.M.T (L)- Revision	AETCOM/PANDEMIC-Feedback(Community Medicine deptt)	AETCOM/PANDEMIC-Feedback(Community Medicine deptt)	Pharm (L-99.3) PH1.37 Androgens & Antagonists Revision	Path Revision PA 26.1,26.2(HI MI) Pnuemonia, Lung abcess	Lunch	Micro SGT-133 & 134: MI 2.1 (VI-IM & HI-PA) Diagnostic methods in Rheumatic fever- Revision
8/31/2025		SUNDAY						

MBBS PHASE II						
TEACHING SCHEDULE FOR AETCOM (37 HRS)						
DATE	TIME	TOPIC	COMPETENCY	NO. OF HOURS	DEPARTMENT	FACULTY
9/21/2024	9-10 am	Module 2.1: The foundations of communication - 2 (5hours)	Demonstrate ability to communicate to patients in a patient, respectful, non-threatening, non-judgmental and empathetic manner	(1 hours)	Pharmacology	
9/28/2024	9-11 am	Module 2.1: The foundations of communication - 2(5hours)	Demonstrate ability to communicate to patients in a patient, respectful, non-threatening, non-judgmental and empathetic manner	(2 hours)	Pharmacology	
10/5/2024	9-11 am	Module 2.1: The foundations of communication - 2 (5hours)	Demonstrate ability to communicate to patients in a patient, respectful, non-threatening, non-judgmental and empathetic manner	(2 hours)	Pharmacology	
10/12/2024	9-11 am	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (5hours)	Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care	(2hours)	Pathology	
10/19/2024	9-10 am	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (5hours)	Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care	(1 hours)	Pathology	
10/26/2024	9-11 am	Module 2.6: Bioethics continued: Case studies on autonomy and decision making (5hours)	Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care	(2 hours)	Pathology	
11/9/2024	9-11 am	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (5 hours)	Identify, discuss and defend, medico-legal, socio-cultural and ethical issues as they pertain to consent for surgical procedures	(2 hours)	Pathology	
11/16/2024	9-11 am	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (5 hours)	Identify, discuss and defend, medico-legal, socio-cultural and ethical issues as they pertain to consent for surgical procedures	(2 hours)	Pathology	
11/23/2024	9-10 am	Module 2.7: Bioethics continued: Case studies on autonomy and decision making (5 hours)	Identify, discuss and defend, medico-legal, socio-cultural and ethical issues as they pertain to consent for surgical procedures	(1 hours)	Pathology	

11/30/2024	9-11 am	Module 2.2 The foundations of bioethics (2 hours)	1. Describe and discuss the role of non-maleficence as a guiding principle in patient care 2. Describe and discuss the role of autonomy and shared responsibility as a guiding principle in patient care 3. Describe and discuss the role of beneficence of a guiding principle in patient care 4. Describe and discuss the role of a physician in health care system 5. Describe and discuss the role of justice as a guiding principle in patient care	(2 hours)	Microbiology	
12/7/2024	9-11 am	Module 2.3: Health care as a right (2 hours)	Describe and discuss the role of justice as a guiding principle in patient care	(2 hours)	Microbiology	
12/14/2024	9-11 am	Module 2.8: What does it mean to be family member of a sick patient? (6 hours)	Demonstrate empathy in patient encounters SH	(2 hours)	Pharmacology	
12/21/2024	9-10 am	Module 2.8: What does it mean to be family member of a sick patient? (6 hours)	Demonstrate empathy in patient encounters SH	(1 hours)	Pharmacology	
1/4/2025	9-11 am	Module 2.8: What does it mean to be family member of a sick patient? (6 hours)	Demonstrate empathy in patient encounters SH	(2 hours)	Pharmacology	
1/18/2025	9-10 am	Module 2.8: What does it mean to be family member of a sick patient? (6 hours)	Demonstrate empathy in patient encounters SH	(1 hours)	Pharmacology	
1/25/2025	9-11 am	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (6 hours)	Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care	(2 hours)	Microbiology	
2/1/2025	9-11 am	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (6 hours)	Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care	(2 hours)	Microbiology	
2/8/2025	9-11 am	Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making (6 hours)	Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care	(2 hours)	Microbiology	

2/15/2025	9-10 am	Module 2.4: Working in a health care team (6 hours)	1. Demonstrate ability to work in a team of peers and superiors 2. Demonstrate respect in relationship with patients, fellow team members, superiors	(1 hours)	Pathology	
2/22/2025	9-11 am	Module 2.4: Working in a health care team (6 hours)	1. Demonstrate ability to work in a team of peers and superiors 2. Demonstrate respect in relationship with patients, fellow team members, superiors	(2 hours)	Pathology	
3/1/2025	9-11 am	Module 2.4: Working in a health care team (6 hours)	1. Demonstrate ability to work in a team of peers and superiors 2. Demonstrate respect in relationship with patients, fellow team members, superiors	(2 hours)	Pathology	
3/8/2025	9-11 am	Module 2.4: Working in a health care team (6 hours)	1. Demonstrate ability to work in a team of peers and superiors 2. Demonstrate respect in relationship with patients, fellow team members, superiors	(2 hours)	Pathology	
3/15/2025	9-10 am	Feedback/assessment		(1 hours)	Pathology	

MBBS PHASE II						
TEACHING SCHEDULE FOR PANDEMIC(28 HRS)						
DATE	TIME	TOPIC	COMPETENCY	NO. OF HOURS	DEPARTMENT	FACULTY
3/22/2025	9-11 am	2.5 Therapeutic strategies including new drug development	1. Describe and discuss the various phases of drug trials 2. Prepare a plan for evaluation of off label use of a drug 3. Organise pharmaco-vigilance activities 4. Discuss ethical aspects of clinical trials in pandemics	(2 hours)	Pharmacology	
3/29/2025	9-11 am	2.5 Therapeutic strategies including new drug development	1. Describe and discuss the various phases of drug trials 2. Prepare a plan for evaluation of off label use of a drug 3. Organise pharmaco-vigilance activities 4. Discuss ethical aspects of clinical trials in pandemics	(2 hours)	Pharmacology	
4/12/2025	9-11 am	2.5 Therapeutic strategies including new drug development	1. Describe and discuss the various phases of drug trials 2. Prepare a plan for evaluation of off label use of a drug 3. Organise pharmaco-vigilance activities 4. Discuss ethical aspects of clinical trials in pandemics	(2 hours)	Pharmacology	
4/19/2025	9-10 am	2.1 Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (4 hours)	1. Describe and discuss the implementation of airborne and contact precautions in a specific clinical situation 2. Describe and discuss the functioning of institutional Infection Control Committee	(1 hours)	Microbiology	
4/26/2025	9-11 am	2.1 Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (4 hours)	1. Describe and discuss the implementation of airborne and contact precautions in a specific clinical situation 2. Describe and discuss the functioning of institutional Infection Control Committee	(2 hours)	Microbiology	
5/3/2025	9-10 am	2.1 Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (4 hours)	1. Describe and discuss the implementation of airborne and contact precautions in a specific clinical situation 2. Describe and discuss the functioning of institutional Infection Control Committee	(1 hours)	Microbiology	
5/3/2025	10-11 am	2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters	1. Describe specimen selection, collection, transportation & storage requirement during a pandemic. 2. Choose and collect the most appropriate clinical sample in a suitable container at the most appropriate time from a suspected case during pandemic (or in a simulated environment). 3. Demonstrate appropriate safety measures in handling and processing of clinical specimens (use of PPE etc.) 4. Discuss various diagnostic modalities available for an infectious disease. 5. Explain sensitivity, specificity, positive predictive value & negative predictive value of each of the diagnostic test/modality. 6. Choose the most appropriate diagnostic test keeping in mind sensitivity, specificity, positive & negative predictive value of the diagnostic test/modality available.	(1 hours)	Microbiology	

5/10/2025	9-11 am	2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters	<ol style="list-style-type: none"> 1. Describe specimen selection, collection, transportation & storage requirement during a pandemic. 2. Choose and collect the most appropriate clinical sample in a suitable container at the most appropriate time from a suspected case during pandemic (or in a simulated environment). 3. Demonstrate appropriate safety measures in handling and processing of clinical specimens (use of PPE etc.) 4. Discuss various diagnostic modalities available for an infectious disease. 5. Explain sensitivity, specificity, positive predictive value & negative predictive value of each of the diagnostic test/modality. 6. Choose the most appropriate diagnostic test keeping in mind sensitivity, specificity, positive & negative predictive value of the diagnostic test/modality available. 	(2 hours)	Microbiology	
5/17/2025	9-10 am	2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters	<ol style="list-style-type: none"> 1. Describe specimen selection, collection, transportation & storage requirement during a pandemic. 2. Choose and collect the most appropriate clinical sample in a suitable container at the most appropriate time from a suspected case during pandemic (or in a simulated environment). 3. Demonstrate appropriate safety measures in handling and processing of clinical specimens (use of PPE etc.) 4. Discuss various diagnostic modalities available for an infectious disease. 5. Explain sensitivity, specificity, positive predictive value & negative predictive value of each of the diagnostic test/modality. 6. Choose the most appropriate diagnostic test keeping in mind sensitivity, specificity, positive & negative predictive value of the diagnostic test/modality available. 	(1 hours)	Microbiology	
5/24/2025	9-11 am	2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters	<ol style="list-style-type: none"> 1. Describe specimen selection, collection, transportation & storage requirement during a pandemic. 2. Choose and collect the most appropriate clinical sample in a suitable container at the most appropriate time from a suspected case during pandemic (or in a simulated environment). 3. Demonstrate appropriate safety measures in handling and processing of clinical specimens (use of PPE etc.) 4. Discuss various diagnostic modalities available for an infectious disease. 5. Explain sensitivity, specificity, positive predictive value & negative predictive value of each of the diagnostic test/modality. 6. Choose the most appropriate diagnostic test keeping in mind sensitivity, specificity, positive & negative predictive value of the diagnostic test/modality available. 	(2 hours)	Microbiology	
5/31/2025	9-11 am	2.2 Emerging and Re-emerging infections, early identification and control of new infections (6 hours)	<ol style="list-style-type: none"> 1. Define emerging and re-emerging infections. Explain reasons or Identify factors responsible for emergence and re-emergence of these infectious diseases. 2. Discuss strategies for early identification, prevention and control of emerging and re-emerging infectious diseases. 3. Discuss the challenges faced in control/ prevention of these infections 	(2 hours)	Community Medicine	

6/7/2025	9-11 am	2.2 Emerging and Re-emerging infections, early identification and control of new infections (6 hours)	1. Define emerging and re-emerging infections. Explain reasons or Identify factors responsible for emergence and re-emergence of these infectious diseases. 2. Discuss strategies for early identification, prevention and control of emerging and re-emerging infectious diseases. 3. Discuss the challenges faced in control/ prevention of these infections	(2 hours)	Community Medicine	
6/21/2025	9-10 am	2.2 Emerging and Re-emerging infections, early identification and control of new infections (6 hours)	1. Define emerging and re-emerging infections. Explain reasons or Identify factors responsible for emergence and re-emergence of these infectious diseases. 2. Discuss strategies for early identification, prevention and control of emerging and re-emerging infectious diseases. 3. Discuss the challenges faced in control/ prevention of these infections	(1 hours)	Community Medicine	
6/28/2025	9-11 am	2.4 Vaccination strategies including vaccine development & Implementation (6 hours)	1. Describe the process of vaccine development. 2. Describe the role of vaccines in disease control and eradication. 3. Describe the steps to prepare a micro plan for vaccination activity at PHC level. 4. Describe the importance of routine vaccination during pandemics. 5. Describe the role of communities in vaccination programmes. 6. Describe the cold chain for vaccine storage and delivery	(2 hours)	Community Medicine	
7/26/2025	9-11 am	2.4 Vaccination strategies including vaccine development & Implementation (6 hours)	1. Describe the process of vaccine development. 2. Describe the role of vaccines in disease control and eradication. 3. Describe the steps to prepare a micro plan for vaccination activity at PHC level. 4. Describe the importance of routine vaccination during pandemics. 5. Describe the role of communities in vaccination programmes. 6. Describe the cold chain for vaccine storage and delivery	(2 hours)	Community Medicine	
8/2/2025	9-11 am	2.4 Vaccination strategies including vaccine development & Implementation (6 hours)	1. Describe the process of vaccine development. 2. Describe the role of vaccines in disease control and eradication. 3. Describe the steps to prepare a micro plan for vaccination activity at PHC level. 4. Describe the importance of routine vaccination during pandemics. 5. Describe the role of communities in vaccination programmes. 6. Describe the cold chain for vaccine storage and delivery	(2 hours)	Community Medicine	
8/23/2025	9-11 am	2.4 Vaccination strategies including vaccine development & Implementation (6 hours)	1. Describe the process of vaccine development. 2. Describe the role of vaccines in disease control and eradication. 3. Describe the steps to prepare a micro plan for vaccination activity at PHC level. 4. Describe the importance of routine vaccination during pandemics. 5. Describe the role of communities in vaccination programmes. 6. Describe the cold chain for vaccine storage and delivery	(2 hours)	Community Medicine	
8/30/2025	9-11 am	Feedback/assessment		(2 hours)	Community Medicine	